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Summary. The predictive capacity of a marker in a population can be
described using the population distribution of risk (Huang et al., 2007;
Pepe et al., 2008a; Stern, 2008). Virtually all standard statistical sum-
maries of predictability and discrimination can be derived from it (Gail
and Pfeier, 2005). The goal of this paper is to develop methods for
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making inference about risk prediction markers using summary measures
derived from the risk distribution. We describe some new clinically mo-
tivated summary measures and give new interpretations to some existing
statistical measures. Methods for estimating these summary measures are
described along with distribution theory that facilitates construction of
condence intervals from data. We show how markers and, more gener-
ally, how risk prediction models, can be compared using clinically relevant
measures of predictability. The methods are illustrated by application to
markers of lung function and nutritional status for predicting subsequent
onset of major pulmonary infection in children suering from cystic bro-
sis. Simulation studies show that methods for inference are valid for use
in practice.
Keywords: Classication; Diagnosis; Prediction; Prognosis; Risk models
1 Background
Let D denote a binary outcome variable, such as presence of disease or occurrence of an
event within a specied time period and let Y denote a set of predictive markers used to
predict a bad outcome, D = 1, or a good outcome, D = 0. For example, elements of the
Framingham risk score (age, gender, total and high-density lipoprotein cholesterol, systolic
blood pressure, treatment for hypertension and smoking) are used to predict occurrence of a
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cardiovascular event within 10 years (http://hp2010.nhlbihin.net/atpiii/calculator.asp). We
write the risk associated with marker value Y = y as risk(y) = P [D = 1jY = y].
Huang et al. (2007) proposed the predictiveness curve to describe the predictive capacity
of Y . It displays the population distribution of risk via the risk quantiles, R() versus ,
where
P [risk(Y )  R()] = :
The inverse of the predictiveness curve is simply the cumulative distribution function (cdf)
of risk(Y )
R 1(p) = P [risk(Y )  p] = Frisk(p)
and correspondingly
R() = F 1risk():
Gail and Pfeier(2005) noted that standard statistical measures used to quantify the
predictive capacity of a risk prediction model can be calculated from the risk distribution
function, Frisk(p). These include measures derived from the receiver operating characteristic
(ROC) curve and the Lorenz curve, predictive values, misclassication rates, and measures
of explained variation. Bura and Gastwirth (2001) used the risk quantiles, R(), to assess
predictors in binary regression models. They proposed a summary index which they called
the total gain.
Summary indices are often used to compare prediction models. The area under the ROC
3
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curve is widely used in practice for this purpose. However there is controversy about its use,
particularly in the cardiovascular research community (Cook, 2007; Pencina et al., 2008).
This has motivated another approach to evaluating risk prediction markers that relies on
dening categories of risk that are clinically meaningful. Several summary indices based
on this notion have been proposed. The reclassication percent and the net reclassication
index (NRI) are such summary measures derived from reclassication tables and they have
recently gained popularity in the applied literature (Ridker et al., 2008; D'Agostino et al.,
2008).
In this paper, we explicitly relate existing and new summary measures of prediction
to the risk distribution, i.e. to the predictiveness curve. We contrast them qualitatively,
paying particular attention to their clinical interpretations and relevance. We then derive
distribution theory that can be used for making statistical inference. Note that rigorous
methods for inference have not been available heretofore for several of the existing summary
measures. Rather the measures are used informally in practice. Small sample performance
is investigated for the new and existing summary measures with simulation studies.
The methods are illustrated with data from 12,802 children with cystic brosis disease.
We describe the data and risk modelling methods in detail later in section 7. Briey, we
compare the capacities of lung function and nutritional measures made in 1995 to predict
onset of a pulmonary exacerbation event during the following year. Overall, 41% of children
had a pulmonary exacerbation in 1996. Figure 1 displays predictiveness curves for two risk
models, one based on lung function (FEV1) and one based on weight. We see from Figure 1
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that lung function is more predictive in the sense that more subjects have lung function based
risks that are at the high and low ends of the risk scale than is true for weight based risks.
Since a good risk marker is one that is helpful to individuals making medical decisions, and
because decisions are more easily made when an individual's risk is high or low than if it is in
the middle, we conclude informally from the curves that lung function is a superior predictor
than weight. We next dene formal summary indices that can be used for descriptive and
comparative purposes and illustrate them with the cystic brosis data.
Figure 1
2 Summary Indices Involving Risk Thresholds
In clinical practice, a subject's risk is calculated to assist in medical decision making. If his
risk is high, he may be recommended for diagnostic, treatment or preventive interventions. If
his risk is low, he may avoid interventions that are unlikely to benet him. In certain clinical
contexts, explicit treatment guidelines exist that are based on individual risk calculations.
For example, the Third Adult Treatment Panel recommends that if a subject's 10 year risk
of a cardiovascular disease exceeds 20% he should consider low density lipoprotein (LDL)-
lowering therapy (Adult Treatment Panel III, 2001). The risk threshold that leads one to
opt for an intervention depends on anticipated costs and benets. These may vary with
individuals' perceptions and preferences (Vickers and Elkin, 2006; Hunink et al., 2006). The
5
Hosted by The Berkeley Electronic Press
choice of threshold may also vary with the availability of health care resources. In this section
we discuss summary indices that depend on specifying a risk threshold. To be concrete we
suppose that the overall risk in the population is high,  = P [D = 1], and that the goal of the
risk model is to identify individuals at low risk, risk(Y ) < pL, where pL is the risk threshold
that denes low risk in the specic clinical context. Analagous discussion would pertain
to a low risk population in which a risk model is sought to identify a subset of individuals
at high risk. Extensions to settings where multiple risk categories are of interest occur in
practice when multiple treatment options are available, and will be discussed at the end of
this section.
For illustration with the cystic brosis data, we choose the low risk threshold pL =
0:25 which contrasts with the overall incidence  = 0:41. Patients with cystic brosis now
routinely receive inhaled antibiotic treatment to prevent pulmonary exacerbations but this
was not the case in the 1990s the time during which our data were collected. If subjects
at low risk, risk(Y ) < pL, in the absence of treatment could be identied, they could
forego treatment and thereby avoid inconveniences, monetary costs and potentially increased
risk of developing therapy resistant bacterial strains associated with inhaled prophylactic
antibiotics.
6
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2.1 Population proportion at low risk
A simple compelling summary measure is the proportion of the population deemed to be at
low risk according to the risk model. This is R 1(pL), the inverse function of the predictive-
ness curve, as noted earlier. A good risk prediction marker should identify more people at
low risk. That is, a better model will have larger values for R 1(pL). In the Cystic Fibrosis
example, we see from Figure 1 that 32% of subjects in the population are in the low risk
stratum based on lung function measures while 11%, are in the low risk stratum according
to weight. A completely uninformative marker would put none in the low risk stratum since
it assigns risk(Y ) =  to all subjects.
2.2 Cases and controls classied as low risk
Another important perspective from which to evaluate risk prediction markers is classication
accuracy (Pepe et al., 2008a , Janes et al., 2008). This is characterized by the risk distribution
in cases, subjects for whom D = 1, and in controls, subjects with a good outcome D = 0.
Specically, a better risk model will classify fewer cases and more controls as low risk (Pencina
et al., 2008). This is desirable because cases should not forego treatment as they may benet
from it. On the other hand, treatment should be avoided for controls since they only suer its
negative consequences. Corresponding summary measures are termed true and false positive
7
Hosted by The Berkeley Electronic Press
rates,
TPR(pL) = P (risk(Y )  pLjD = 1); FPR(pL) = P (risk(Y )  pLjD = 0):
Higher TPR(pL) and lower FPR(pL) are desirable.
Figure 2 shows cumulative distributions of risk(Y ) in cases and controls separately. From
this, TPR(p) and FPR(p) can be gleaned for any value of p. We see that the proportion of
controls in the low risk stratum is much larger when using lung function as the risk prediction
marker than for weight, 1-FPR(pL) = 46% for lung function as opposed to 15% for weight.
However the proportion of cases whose risks exceed pL is also lower for the lung function
model (TPR(pL) = 87%) than for the weight model (TPR(pL) = 93%)
Figure 2
Observe that TPR(pL) and FPR(pL) are indexed by the threshold pL. This contrasts
with the display of TPR and FPR that constitutes the ROC curve. ROC curves (Figure
3) suppress the risk thresholding values by showing TPR just as a function of FPR, not
TPR and FPR as functions of risk threshold (Figure 2). When specic risk thresholds dene
clinically meaningful risk categories, the TPR and FPR associated with those risk category
denitions are of intrinsic interest, more so than the TPR achieved at a xed FPR value.
Figure 3
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2.3 Event rates in risk strata
Another pair of summary measures is the event rates in the two risk strata. These can be
thought of as predictive values, PPV(pL) and 1-NPV(pL), dened as
PPV(pL) = P (D = 1jrisk(Y ) > pL); and 1-NPV(pL) = P (D = 1jrisk(Y ) < pL): (1)
PPV(pL) is the event rate in the high risk stratum and 1-NPV(pL) is the event rate in the
low risk stratum. For a good marker, the event rate PPV(pL) will be high and the event
rate 1-NPV(pL) will be low.
By applying Bayes theorem to (1), PPV and NPV can be written in terms of TPR and
FPR:
PPV(p) =

1  
TPR(p)
FPR(p)
; NPV(p) =
1  

1  FPR(p)
1  TPR(p) ; (2)
These expressions facilitate estimation of PPV(p) and NPV(p), which we discuss in section 4.
Event rates are also functions of the predictiveness curve. Specically they average the
curve over the ranges (L; 1) and (0; L) where L = R
 1(pL).
PPV(pL) =
Z 1
L
R(u)du=(1  L); and 1-NPV(pL) =
Z L
0
R(u)du=L:
For the cystic brosis example, estimates of the event rates, 1-NPV(pL) and PPV(pL),
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are 17% and 53% for the risk strata dened by lung function. In contrast the event rates
are much closer to each other, 24% and 43%, in the two risk strata dened by weight. Again
lung function appears to be the better predictor of low risk. Not only is R 1(pL), the size of
the low risk stratum, bigger when using lung function but 1-NPV(pL), the event rate in the
low risk stratum, is also smaller.
2.4 th Risk percentile
In the applied literature, variables are often categorized using quantiles. In this vein, cate-
gories of risk are sometimes dened using risk quantiles for which we have used the notation
R(). For example, Ridker et al. (2000) used quartiles of risk and noted that high sensitivity
c-reactive protein (hs-CRP) was more predictive of cardiovascular risk than standard lipid
screening because the level of hs-CRP in the highest versus lowest quartile was associated
with a much higher relative risk for future coronary events than was the case for standard
lipid measurements.
Another context in which R() is well motivated is when availability of medical resources
is limited. Suppose resources are available to provide an intervention to a fraction 1   of
the population, those 1    at highest risk. Since R() is the corresponding risk quantile,
subjects given the intervention have risks  R(). A marker or risk model for which R()
is larger is preferable because it ensures that those receiving intervention are at greater risk
of a bad outcome in the absence of the intervention.
10
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In the cystic brosis example, suppose the 10% of the population deemed to be at high-
est risk will be treated. If lung function is used to calculate risk, subjects with risks at or
above 0.76 receive treatment. On the other hand if weight is used to calculate risk, subjects
whose risks are as low as 0.52 will be oered treatment.
2.5 Risk threshold yielding specied TPR or FPR
In a diagnostic setting, it may be important to ag most people with disease as high risk
so that people with disease get necessary treatment. In other words, we may require that
the TPR exceed a certain minimum value, TPR=t. The corresponding risk threshold is an
important entity to report. We denote it by R(T (t)). The decision rule that yields TPR=t,
requires people whose risks are as low as R(T (t)) to undergo treatment. If the treatment
is cumbersome or risky the decision rule may be unacceptable or unethical if the threshold
R(T (t)) is low.
In screening healthy populations for a rare disease such as ovarian cancer, the false
positive rate must be very low in order to avoid large numbers of subjects undergoing unnec-
essary medical procedures. The risk threshold that yields an acceptable FPR must also be
acceptable for individuals as a threshold for deciding for or against medical procedures. To
maintain a very low FPR, the risk threshold may be very high in which case the decision rule
would not be ethical. Reporting the risk threshold that yields specied FPR=t is therefore
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often important in practice and we denote the threshold by R(F (t)).
Unlike other predictiveness summary measures, R(T (t)) and R(F (t)) may not be suited
to the task of comparing markers. It is not clear that a specic ordering of thresholds is
always preferable. In the cystic brosis example, the risk threshold that yields TPR=0.85 is
0.27 when the calculation is based on lung function, but 0.32 when weight is used. Observe
that another consideration is the corresponding false positive rate which is 0.50 for lung
function and 0.72 for weight. If one wanted to control the false positive rate, at FPR=0.15
say, the corresponding risk thresholds are 0.54 for lung function and 0.51 for weight. Observe
that the lung function based risk threshold is lower than that for weight when controlling
the TPR but higher when controlling the FPR.
2.6 Risk reclassication measures
Several summary measures that rely on dened risk categories have been proposed recently.
The context for their denition has been when comparing a baseline risk model with one
that adds a novel marker to the baseline predictors using risk reclassication tables that
involve 3 or more categories of risk. It is illuminating to consider these measures in our
much simplied context, where only 2 risk categories dened by a single risk threshold pL
are of interest and when the baseline model involves no covariates at all so that the baseline
risk is equal to  for all subjects. We discuss the more complex setting later.
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Cook (2007) proposes the reclassication percent to summarize predictive information
in a model. In our context, all subjects are considered high risk under the baseline model
because  > pL. The reclassication percent is therefore the proportion of subjects classied
as low risk according to the risk model involving Y . This is exactly the summary index
R 1(pL) discussed earlier.
Pencina et al. (2008) criticize the reclassication percent because it does not distinguish
between desirable risk reclassications (up for cases and down for controls) and undesirable
risk reclassications (down for cases and up for controls). They propose the net reclassi-
cation improvement (NRI) summary statistic as an alternative. We use "up" and "down"
to denote changes of one or more risk categories in the upward and downward directions,
respectively, for a subject between their baseline and augmented risk values. The NRI is
dened as
NRI = [P (upjD = 1)  P (downjD = 1)]  [P (upjD = 0)  P (downjD = 0)]:
In our simple context it is easy to see that
NRI = TPR(pL)  FPR(pL)
where TPR(pL) and FPR(pL) were discussed earlier. We see that in the 2 category setting
the NRI statistic is equal to Youden's index (Youden, 1950). Youden's index has been
criticized because implicitly it weighs equally the consequences of classifying a case as low
13
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risk, i.e. a case failing to receive intervention, and classifying a control as high risk, i.e.
a control subjected to unnecessary intervention. Most often the costs and consequences of
these mistakes will dier greatly for cases and controls. Therefore we recommend reporting
the two components of the NRI separately, TPR(pL) and FPR(pL). Values were reported for
the cystic brosis study above. The corresponding NRI values are 0.33=0.87-0.54 for lung
function and 0.08=0.93-0.85 for weight.
2.7 Extensions and discussion
A key use of summary measures is to compare dierent risk models. One can quantify the
dierence in performance between two risk models by taking the dierence between summary
measures derived from the two models. In the cystic brosis example discussed here, the
two risk models involve completely dierent markers. However, one could also entertain two
models that involve some common predictors. The setting in which risk reclassication ideas
have emerged, is where one model involves standard baseline predictors and the other includes
a novel marker in addition to the baseline predictors. Taking the dierence in summary
measures for the two models is a sensible way of assessing improvement in performance in
this context too.
Recall that when only 2 risk categories (low versus high) exist, Cook's reclassication
percent is equal to R 1(pL) when the baseline risk does not depend on baseline covariates.
However, the reclassication percent is not equal to the dierence of values for R 1(pL)
14
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between the baseline and augmented models when the baseline model does involve covari-
ates. In general, even when two models have exactly the same predictive performance, the
reclassication percent is typically non-zero. In fact it has been shown to vary dramatically
with correlations between predictors in one model versus another (Janes et al., 2008). This
measure therefore does not seem well suited for gauging the dierence between predictive
capacities of two models. Instead we suggest that one simply focus on the dierence in
proportions of subjects classied as low (or high) risk with the two models, i.e. dierences
in R 1(pL).
We represented the NRI statistic as TPR(pL)-FPR(pL) in the simple setting. It is easy to
show that when two models involve covariates, the NRI statistic to compare the two models
is the dierence (TPR1(pL)-TPR2(pL))-(FPR1(pL)-FPR2(pL)) where subscripts 1 and 2 are
used to index the two models. In analogy with our earlier discussion, we recommend reporting
the two comparative components separately, TPR1(pL)-TPR2(pL) and FPR1(pL)-FPR2(pL),
rather than their dierence, the NRI, because typically changes in TPR should be weighted
dierently than changes in FPR.
Summarizing data is dicult when more than two risk categories are involved. Statistics
such as the NRI have been criticized because they do not distinguish between changes of
one risk category and more than one risk category (Pepe et al., 2008b). In a similar vein,
when 3 risk categories exist with specic treatment recommendations for each, misclassifying
a case as being in the lowest risk level may be more serious than misclassifying him as in
the middle category. Similarly, misclassifying a control as being in the highest risk level
15
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may be more serious than misclassifying him as being in the middle category. Without
specifying utilities associated with dierent types of misclassications, any accumulation
of data across risk categories is dicult to justify. For these settings we propose use of a
vector of summary statistics distinguished by the risk thresholds. For example, suppose we
consider three risk categories for the cystic brosis study dened by two thresholds pL = 0:25
and pH = 0:75. We could report: the proportions of subjects in the highest and lowest
categories, (1   R 1(pH); R 1(pL)); the proportions of cases and controls in each category,
(TPR(pH); 1  TPR(pL)) and (FPR(pH); 1  FPR(pL)); and so forth.
Although statistical summaries that depend on clinically meaningful risk thresholds are
appealing, the choice of risk thresholds is often uncertain. Dierent clinicians or policy
makers may choose dierent risk categorizations. This argues for displaying the risk distri-
butions as continuous curves since one can then read from them summary indices described
here using any risk threshold of interest to the reader.
3 Threshold Independent Summary Measures
Classic measures that describe the predictive strength of a model can be interpreted as
summary indices for the predictiveness curve. We describe the relationships next. These
measures can compliment the display of risk distributions for several models when no spe-
cic risk thresholds are of key interest. In addition, formal hypothesis tests to compare
predictiveness curves can be based on them.
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3.1 Proportion of explained variation
The proportion of explained variation, also called R2, is the most popular measure of pre-
dictive power for continuous outcomes and is popular for binary outcomes too. It is most
commonly dened as
PEV  var(D)  E(var(DjY ))
var(D)
:
But it can also be written as
PEV = var(risk(Y ))=(1  );
because var(D)=E(var(DjY ))+var(E(DjY )) and E(DjY ) = P (D = 1jY ) = risk(Y ). PEV
is a standardized measure of the variance in risk(Y ) since (1 ) in the denominator is the
risk variance for an ideal marker that predicts risk(Y ) = 1 for cases and risk(Y ) = 0 for
controls. Hu et al. (2006) noted that PEV can also be written as the correlation between D
and risk(Y ).
An unintuitive but interesting and simple interpretation for PEV is as the dierence
between the averages of risk(Y ) for cases and controls(Pepe et al., 2008b),
PEV = E[risk(Y )jD = 1]  E[risk(Y )jD = 0]:
17
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In summary for the cystic brosis data, PEV, calculated as 0.22 for the lung function
measure and 0.05 for weight, can be interpreted as variances of risk distributions displayed
in Figure 1 standardized by the ideal variance of 0:41 (1  0:41) = 0:24, or as dierences
in means of distributions shown in Figure 2. In Figure 1, var(risk(Y )) = 0:053 for lung
function and 0.012 for weight yielding 0.22 and 0.05 respectively when divided by 0.24. On
the other hand in Figure 2, case and control mean risks are 0.54 and 0.32 for lung function
while they are 0.44 and 0.39 for weight, again yielding 0.54-0.32=0.22 and 0.44-0.39=0.05
for the PEV values calculated as the dierences in means.
Pencina et al. (2008) employ the PEV summary measure to gauge the improvement in
risk prediction when clinically relevant risk thresholds do not exist. They do not recognize
it as the proportion of explained variation but call it integrated discrimination improvement
(IDI) and note that it has another interpretation as Youden's index integrated uniformly
over (0,1):
PEV =
Z
Y I(p)dp;
where Y I(p) = P (risk(Y ) > pjD = 1)   P (risk(Y ) > pjD = 0) is Youden's index for
the binary decision rule that is positive when risk(Y ) > p. In other words, PEV can also
be interpreted as the dierence between integrated TPR(p) and FPR(p) functions dened
earlier.
In a commentary on the Pencina et al. paper, Ware and Cai (2008) suggest that IDI,
denoted here by PEV, does not depend on the overall event rate,  = P (D = 1). We disagree.
18
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To illustrate, suppose we have a single marker with risk function risk(Y ) increasing in Y .
Then
PEV =
Z
(P (risk(Y ) > pjD = 1)  P (risk(Y ) > pjD = 0))dp
=
Z
(P (Y > yjD = 1)  P (Y > yjD = 0))@risk(Y )
@Y
jY =ydy
Here, the conditional probabilities, P (Y > yjD = 1) and P (Y > yjD = 0), are independent
of prevalence, , but @risk(Y )
@Y
is a function of . To demonstrate, consider a simple linear
logistic regression model,
logitP (D = 1jY ) = 0 + 1Y: (3)
and note that
@risk(Y )
@Y
=
@P (D = 1jY )
@Y
= 1P (D = 1jY )f1  P (D = 1jY )g:
Since P (D = 1jY ) = P (Y jD=1)
P (Y jD=0)

1 =f1 + P (Y jD=1)P (Y jD=0) 1 g, clearly varies with , so does its
derivative. Figure 4 shows the relationship between PEV and  for a marker Y that is
standard normally distributed in controls and normally distributed with mean 1 and variance
1 in cases. The risk is a simple linear logistic risk function (equation (3)). As  increases
from 0 to 1, we see that PEV increases then decreases with maximum occurring at  = 0:5.
Janssens et al. (2006) also demonstrated dependence of PEV on  through a simulation
19
Hosted by The Berkeley Electronic Press
study.
Figure 4
The proportion of explained variation has been dened in other ways, notably based
on notions of log likelihood (deviance). Gail and Pfeier (2005) note that these can also be
calculated from the risk distribution. However, Zheng and Agresti (2000) make the point that
these summary measures are dicult to interpret and we concur wholeheartedly. Therefore,
we do not pursue them further in this paper but note that methods for inference could be
developed in analogy with those we develop here for PEV.
3.2 Total Gain
Total gain, proposed by Bura and Gastwirth (2001) is dened as ,
TG =
Z 1
0
jR()  jd: (4)
This is the area sandwiched between the predictiveness curve and the horizontal line at ,
which is the predictiveness curve for a completely uninformative marker assigning risk(Y ) =
 to all subjects. TG is appealing because it can be visualized directly from the predictiveness
curve. For a perfect risk prediction model, the predictiveness curve is a step function rising
from 0 to 1 at  = 1  . The corresponding TG is 2(1  ).
20
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Other interpretations can be made for TG. Huang and Pepe (2008b) have shown that
TG is equivalent to the Kolmogorov-Smirnov measure of distance between risk distributions
for cases and controls. This is an ROC summary index (Pepe, 2003, page 80):
TG = 2(1  )suptfROC(t)  tg (5)
= 2(1  )maxpfTPR(p)  FPR(p)g; (6)
In fact we can write this more simply.
Result
TG = 2(1  )fTPR()  FPR()g (7)
Proof
Let  be the point where R() = . We have
TG =
Z 
0
(  R())d +
Z 1

(R()  )d:
Furthermore, because  =
R 
0
R()d +
R 1

R()d and  =
R 1
0
d, setting these two terms
equal it follows that Z 
0
(  R())d =
Z 1

(R()   )d:
21
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Therefore TG can be written as
TG = 2
Z 1

(R()  )d
= 2
Z 1

R()d   2(1  )
= 2TPR()  2(1  R 1())
because TPR() =
R 1

R()d=. Moreover, since 1  R 1() = TPR() + (1  )FPR(),
the above representation of TG can be further simplied to 2(1  )fTPR()   FPR()g.
This representation of TG is useful for estimation and for deriving asymptotic distribution
theory. Interestingly, by equating (6) and (7), we nd that the maximum value of TPR(p)-
FPR(p) occurs at the risk threshold p = . Another short proof follows by taking its
derivative. In particular, since
TPR(R())   FPR(R()) =
R 1

R(u)du

+
R 1

(1 R(u))du
1   ; (8)
taking the derivative of the right side with respect to  and setting it to 0, we have
f1  R()

g   f1  1  R()
1   g = 0
at the solution. That is, the solution is at R() = . In the same illustrative setting used
above, where  = 0:2, Y is standard normal in controls and normal with mean 1 and variance
1 in cases, we see from Figure 5 how TPR(p)-FPR(p) varies with p. The maximum value,
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0.39, is achieved at p = 0:2, i.e. at p = .
Figure 5
Another appealing feature of TG is that after it is standardized by 2(1  ), the total gain
for a perfect marker, it is functionally independent of . Let's use TG to denote standardized
total gain
TG  TG
2(1  )
so that TG 2 [0; 1]. We will focus on TG here. It is independent of disease prevalence because
of it's interpretation as the Kolmogorov-Smirnov ROC summary index. Moreover, based on
the results above, TG is simply interpreted as the dierence between the proportions of cases
and controls with risks above the average,  = P (D = 1) = E(risk(Y )).
In the cystic brosis example, TG based on lung function is 0.20, while TG based on
weight is 0.09. Since the overall event rate is =41%, the corresponding standardized TG
values are TG=0.42 for lung function and TG =0.20 for weight.
3.3 Area under the ROC curve and further discussion
The area under the ROC curve is widely used to summarize and compare predictive markers
and models. It can be interpreted simply as the probability of correctly ordering subjects
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with and without events using risk(Y ):
AUC = P (risk(Y1) > risk(Y2)jD1 = 1; D2 = 0)
However, it has been criticized widely for having little relevance to clinical practice (Cook,
2007; Pepe and Janes, 2008; Pepe et al., 2007). In particular, the task facing the clinician in
practice is not to order risks for two individuals. Part of the appeal of the AUC, however, lies
in the fact that it depends neither on prevalence, , nor on risk thresholds. Yet in the context
of risk prediction within a specic clinical population, these attributes may be weaknesses.
In particular, when specic risk thresholds are of interest, the ROC curve hides them. In
Figure 3, we plot the ROC curves for risk based on lung function and on weight. The AUC
values are 0.771 and 0.639, respectively.
Interestingly all of the measures discussed here can be thought of as the mathematical
distance between risk distributions for cases and controls (Figure 2) measured in dierent
ways. The PEV is the dierence in the means of case and control risk distributions. The TG
is the Kolmogorov-Smirnov measure and we have shown that this is equal to the dierence
between the proportions of cases and controls with risks larger than . The AUC is equivalent
to the Wilcoxon measure of distance between risk distributions for cases and controls.
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4 Estimation of Summary Measures
We now turn to estimation of summary indices from data. We focus on the scenario where
Y is a single continuous marker. We also allow Y to be a predened combination of multiple
markers. For example, the score may be derived from a training dataset and our task is to
evaluate the combination score using a test dataset.
We use the following notation: Y , YD and Y D are marker measurements from the gen-
eral, case and control populations, respectively. Let F , FD and F D be the corresponding
distribution functions and let f , fD and f D be the density functions. We assume the risk,
risk(Y ) = P (D = 1jY ), is monotone increasing in Y . Under this assumption we have
R() = PfD = 1jY = F 1()g. Thus the curve R() vs.  is the same as the curve
risk(Y ) vs F (Y ) and the predictiveness curve can be obtained by rst estimating the risk
model risk(Y ), and then the marker distribution F (Y ). Let YDi, i = 1; :::; nD be the nD
independent identically distributed observations from cases, and Y Di , i = 1; :::; n D be the n D
independent identically distributed observations from controls. We write Yi, i = 1; :::; n for
fYD1 ; :::; YDn
D
; Y D1 ; :::; Y Dn D
g where n = nD + n D.
Suppose the risk model is risk(Y ) = P (D = 1jY ) = G(; Y ), where
logitfG(; Y )g = 0 + h(1; Y );
and h is some monotone increasing function of Y . This is a very general formulation. As a
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special case, logitfG(; Y )g could be as simple as 0 + 1Y with 1 > 0, the ordinary linear
logistic model. We consider estimation rst under a cohort or cross sectional design and
later discuss case-control designs for which the logistic regression formulation is particularly
helpful.
4.1 Cohort Design
Suppose we have n independent identically distributed observations (Yi; Di) from the popula-
tion. Maximum likelihood estimates of  can be obtained, denoted by ^, as well as empirical
estimates of F , FD, F D, and , denoted by F^ , F^D, F^ D, and ^. We use these to calculate
estimated summary indices. Summary measures that involve risk thresholds are the risk
quantile, R(), the population proportion with risk below p, R 1(p), cases and controls with
risks above p, TPR(p) and FPR(p), event rates in risk strata, PPV(p) and 1-NPV(p), and
the risk thresholds yielding specied TPR or FPR, R(T (t)) and R(F (t)).
We plug ^ and F^ into G to get estimators of R(), and R 1(p):
R^() = Gf^; F^ 1()g for  2 (0; 1);
R^ 1(p) = F^fG 1(^; p)g for p 2 fR() :  2 (0; 1)g:
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Estimates of cases and controls with risks above p are:
^TPR(p) = 1  F^DfG 1(^; p)g for p 2 fR() :  2 (0; 1)g;
^FPR(p) = 1  F^ DfG 1(^; p)g for p 2 fR() :  2 (0; 1)g:
We write the event rates in risk strata in terms of TPR(p) and FPR(p) to facilitate their
estimation:
^PPV(p) =
^
1  ^
^TPR(p)
^FPR(p)
for p 2 fR() :  2 (0; 1)g
^1  NPV(p) = 1  1  ^
^
1  ^FPR(p)
1  ^TPR(p) for p 2 fR() :  2 (0; 1)g
In a cohort study, these estimates are equal to the empirical proportions of cases amongst
those with estimated risks above and below p. However, the formulations here are valid in a
case-control study too. Finally risk thresholds yielding specied TPR or FPR are obtained
by rst calculating the corresponding quantile of Y and then plugging it into the tted risk
model:
R^(T (t)) = Gf^; F^ 1D (T (t))g for TPR = 1  T (t);
R^(F (t)) = Gf^; F^ 1D (F (t))g for FPR = 1  T (t)
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Summary measures that do not involve specic risk thresholds are proportion of explained
variation, PEV, standardized total gain, TG, and area under the ROC curve, AUC. Recall
that PEV is the dierence between mean risk in cases and in controls. Sample means of
estimated risks yield an estimator of PEV:
^PEV =
Z
G(^; Y )dF^D(Y ) 
Z
G(^; Y )dF^ D(Y ):
On the other hand, TG, can be expressed as the dierence between the proportion of
cases and controls with risks less than . We write:
T^G = fF^ D(G 1(^; ^))  F^D(G 1(^; ^))g:
Finally AUC is estimated as the proportion of case-control pairs where the estimated risk
for the case exceeds that of the control
^AUC =
1
nDn D
nDX
i=1
n DX
j=1
I(G(^; YDi) > G(^; Y Dj)):
Since G(; Y ) is increasing in Y , this is the same as the standard empirical estimator of the
AUC based on Y ,
^AUC =
1
nDn D
nDX
i=1
n DX
j=1
I(YDi > Y Dj):
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4.2 Case-Control Design
Case-control studies are often conducted in the early phases of marker development(Pepe et
al., 2001; Baker et al., 2002). Compared to cohort studies, they are smaller and more cost
ecient. Since early phase studies dominate biomarker research, it is crucial that estimates
of statistical measures of performance accommodate case-control designs. In this section, we
describe estimation under a case-control design assuming that an estimate of prevalence, ^
is available. The value ^ may be derived either from a cohort which is independent from
the case-control sample, or from the parent cohort within which the case-control sample is
nested. As a special case one can assume  is known or xed without sampling variability. In
determining populations where risk markers may or may not be useful, predictiveness curves
could be evaluated for various specied xed values of .
In case-control studies, we sample xed numbers of cases and controls, nD and n D,
respectively. As a consequence, the intercept of the logistic risk model is not estimable. But
by adjusting the intercept, we can still estimate the true risk in the population. In particular
let S indicate case-control sampling. In the case-control study the risk model can be written
as
logitfG(S; Y )g = 0S + h(1S; Y );
where 0S = 0   log n DnD

1  and 1S = 1, and 0 and 1 are population based intercept and
slope. Therefore, having calculated maximum likelihood estimates for 0S and 1 from the
case-control study, we use ^0S + log(
n D
nD
^
1 ^ ) to estimate the population intercept 0.
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The marker distribution in the population, F , cannot be estimated directly because of
the case-control sampling design. However, since case and control samples are representative,
empirical estimates of FD and F D are valid which we have denoted by F^D and F^ D. Therefore
we estimate F with F^ = ^F^D + (1  ^)F^ D.
Estimates of the predictiveness summary measures can then be obtained by plugging
corresponding values for ^, F^ , F^D, F^ D and ^ into the expressions given earlier. These esti-
mates are called semiparametric \empirical" estimates by Huang and Pepe (2008a) because
FD and F D are estimated empirically. The semiparametric likelihood framework also allows
one to estimate FD and F D using maximum likelihood (Qin and Zhang, 1997, Zhang, 2000).
Huang and Pepe (2008a) compared the performance of semiparametric \empirical" estima-
tors of the predictiveness curve with semiparametric maximum likelihood estimators. Gains
in eciency by using maximum likelihood are typically small. We use empirical estimators
of FD and F D here, because this approach is intuitive and easy to implement. Moreover,
they estimate important estimable quantities even when the risk model is misspecied. For
example, ^TPR(p) is the proportion of cases whose calculated risks (calculated under the as-
sumed model) exceed p, ^PEV is the dierence in mean calculated risk for cases and controls,
and so forth.
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5 Asymptotic Distribution Theory
In this section, we present asymptotic distribution theory for all of the summary measures
dened in previous sections. Results for pointwise estimators of R() and R 1(p)were pre-
viously reported by Huang et al. (2007) and Huang and Pepe (Biometrika, in press), but
for completeness we restate them here. Theory for the empirical estimator of AUC is not
reported here since it is well established (Pepe, 2003, page 105). Derivations of our results
are provided in the Appendix. In addition, in the Appendix, we detail the components of
the asymptotic variance expressions separately for case-control and cohort study designs.
Assume the following conditions hold:
(1) G(s; Y ) is a dierentiable function with respect to s and Y at s = , Y = F 1().
(2) G 1(s; p) is continuous, and @G 1(s; p)=@s exists at s = .
Theorem As n ! 1, each of the following random variables converges to a mean zero
normal random variable:
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(i)
p
n(R^ 1(p)  R 1(p)), with variance
1(p)
2 = var(
p
n(F^ (G 1(; p))  F (G 1(; p)))) + (@R
 1(p)
@
)T var(
p
n(^   ))(@R
 1(p)
@
)
+ 2(
@R 1(p)
@
)T cov(
p
n(^   );pn(F^ (G 1(; p))  F (G 1(; p))));
(ii)
p
n( ^TPR(p)  TPR(p)), with variance
2(p)
2 = var(
p
n(F^D(G
 1(; p))   FD(G 1(; p)))) + (@TPR(p)
@
)Tvar(
p
n(^   ))(@TPR(p)
@
)
  2(@TPR(p)
@
)T cov(
p
n(^   );pn(F^D(G 1(; p))   FD(G 1(; p))));
(iii)
p
n( ^FPR(p)  FPR(p)), with variance
3(p)
2 = var(
p
n(F^ D(G
 1(; p))   F D(G 1(; p)))) + (
@FPR(p)
@
)Tvar(
p
n(^   ))(@FPR(p)
@
)
  2(@FPR(p)
@
)T cov(
p
n(^   );pn(F^ D(G 1(; p))   F D(G 1(; p))));
(iv)
p
n( ^PPV (p)  PPV (p)), with variance
4(p)
2 = PPV (p)2(1  PPV (p))2f( 2(p)
2
TPR(p)2
+
3(p)
2
FPR(p)2
+
2
2(1  )2 )
  2( cov1
TPR(p)FPR(p)
  cov2
TPR(p)(1  ) +
cov3
FPR(p)(1  ))g
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where 2 is the asymptotic variance of
p
n(^  ) and
cov1 = cov(
p
n( ^TPR(p)  TPR(p));pn( ^FPR(p)   FPR(p))) (9)
cov2 = cov(
p
n( ^TPR(p)  TPR(p));pn(^  )) (10)
cov3 = cov(
p
n( ^FPR(p)  FPR(p));pn(^  )); (11)
(v)
p
n( ^NPV (p)  NPV (p)), with variance
5(p)
2 = NPV (p)2(1 NPV (p))2f( 5(p)
2
(1  TPR(p))2 +
6(p)
2
(1  FPR(p))2 +
2
2(1  )2 )
  2( cov1
(1  TPR(p))(1  FPR(p)) +
cov2
(1  TPR(p))(1  )  
cov3
(1  FPR(p))(1  ) )g;
(vi)
p
n(R^()  R()), with variance
6()
2 = (
@R()
@
)2var(
p
n(F^ (F 1())   )) + (@R()
@
)Tvar(
p
n(^   ))(@R()
@
)
  2(@R()
@
)cov(
p
n(^   );pn(F^ (F 1())  ))(@R()
@
);
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(vii)
p
n(R^(T (t))  R(T (t))) where TPR=1  T (t) is pre-specied, with variance
7(t)
2 = (
@R(T (t))
@t
)2var(
p
n(F^D(F
 1
D (T (t)))  t)) + (
@R(T (t))
@
)Tvar(
p
n(^   ))(@R(T (t))
@
)
  2(@R(T (t))
@t
)cov(
p
n(^   );pn(F^D(F 1D (T (t)))  t))(
@R(T (t))
@
);
(viii)
p
n(R^(F (t)) R(F (t))) where FPR=1  F (t) is pre-specied, with variance
8(t)
2 = (
@R(F (t))
@t
)2var(
p
n(F^ D(F
 1
D
(F (t)))  t)) + (@R(F (t))
@
)T var(
p
n(^   ))(@R(F (t))
@
)
  2(@R(F (t))
@t
)cov(
p
n(^   );pn(F^ D(F 1D (F (t)))  t))(
@R(F (t))
@
);
(ix)
p
n( ^PEV   PEV ), with variance
29 =
var(G(; YD))
nD=n
+
var(G(; Y D))
n D=n
+ (
Z
@G(; y)
@
dFD(y) 
Z
@G(; y)
@
dF D(y))
T
var(
p
n(^   )) (
Z
@G(; y)
@
dFD(y) 
Z
@G(; y)
@
dF D(y))
+ 2(
Z
@G(; y)
@
dFD(y) 
Z
@G(; y)
@
dF D(y))
T
fcov(pn(^   );pn
Z
G(; Y )d(F^D(Y )  FD(Y )))
  cov(pn(^   );pn
Z
G(; Y )d(F^ D(Y )  F D(Y )))g;
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(x)
p
n(T^G  TG), with variance
210 = 1   21;2 + 2;
where
1 = var(
p
n( ^TPR(^)  TPR())); (12)
2 = var(
p
n( ^FPR(^)  FPR())); (13)
1;2 = cov(
p
n( ^TPR(^)  TPR());pn( ^FPR(^)  FPR())): (14)
6 Simulation Studies
We performed simulation studies to investigate the validity of using large sample theory for
making inference in nite sample studies, and to compare it with inference using bootstrap
resampling. Data were simulated under a linear logistic risk model. Specically we employed
a population prevalence of  = 0:2 and generated marker data according to Y D  N(0; 1) and
YD  N(1; 1). The correct form for G(; Y ) was employed in tting the risk model, namely
a linear logistic model. For each simulated dataset, estimates of summary indices were
calculated and their corresponding variances were estimated using the analytic formulae from
the asymptotic theory. Variance estimates were also calculated using bootstrap resampling.
Sample sizes ranged from 100 to 2000 and 5000 simulations were conducted for each scenario.
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Simulation studies were conducted for case-control study designs as well as for cohort
study designs. For the case-control scenario, we simulated nested case-control samples within
the main study cohort employing equal numbers of cases and controls and with size of the
cohort equal to 5 times that of the case-control study. The estimator ^ is calculated from the
main study cohort and sampling variability in summary estimates due to ^ is acknowledged
in making inference. Separate resampling of cases and controls was done for the nested
case-control scenarios.
Table 1-3 displayed results for the summary indices under cohort study designs, while
Table 4-6 are corresponding results under case-control study designs. Indeed, extensive
simulation results for estimates of points on the predictiveness curve, R() and R 1(p), were
already reported by Huang and Pepe (2008a). For completeness, we also included results
for these two estimates under our simulation. We found little bias in the estimated values.
Moreover estimated standard deviations based on asymptotic theory agree well with the
actual standard deviations and with those estimated from bootstrap resampling. Coverage
probabilities were excellent when sample sizes were moderate to large. We observed some
under-coverage and some over coverage with small sample sizes (n = nD + n D = 100). Not
surprisingly this occurred primarily at the boundaries of the case and control distributions
and was not an issue for the overall summary measures, PEV, TG and AUC. Generally,
coverage based on percentiles of the bootstrap distribution are somewhat better than those
based on assumptions of normality, but the dierence shrinks for larger n.
36
http://biostats.bepress.com/uwbiostat/paper342
7 The Cystic Fibrosis Data
Cystic brosis is an inherited chronic disease that aects the lungs and digestive system
of people. A defective gene and its protein product cause the body to produce unusually
thick, sticky mucus which clogs the lungs and leads to life-threatening lung infections, and
also obstructs the pancreas and stops natural enzymes from helping the body break down
and absorb food. The main culminating event that leads to death is acute pulmonary
exacerbations, i.e. lung infection requiring intravenous antibiotics.
The data for analysis here is from the Cystic Fibrosis Registry, a database maintained by
the Cystic Fibrosis Foundation that contains annually updated information on over 20,000
people diagnosed with CF and living in the USA. In order to illustrate our methodology,
we consider FEV1, a measure of lung function, and weight, a measure of nutritional status,
as measured in 1995 to predict occurrence of pulmonary exacerbation in 1996. Data from
12,802 patients 6 years of age and older are analyzed. 5245 subjects (41%) had at least one
pulmonary exacerbation. A child's weight is standardized for age and gender by reporting
his/her percentile value in a healthy population of children of the same age and gender
(Hamill, et al., 1977), while FEV1 is standardized for age, gender and height in a dierent
way, explicit formulae were provided by Knudson et al. (1983). We modelled the risk
functions using logistic regression models with weight and FEV1 entered the model as linear
terms, and both are negated to satisfy the assumption that increasing values are associated
with increasing risk. Figure 1 shows the predictiveness curves for the entire cohort and Figure
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2 shows the risk distributions separately for cases (those who had a pulmonary exacerbation)
and for controls.
First, we use the entire cohort to estimate predictiveness summary measures for weight
and lung function. Table 3 shows the point estimates discussed earlier in sections 2 and
3. Here we provide condence intervals based on asymptotic distribution theory and on
bootstrap resampling. Observe that standard deviations are all small and that corresponding
condence intervals are very tight. Bootstrap condence intervals are almost identical to
those based on asymptotic theory.
We used the summary indices as the basis for hypothesis tests to formally compare the
predictive capacities of FEV1 and weight. The dierence between estimates of the indices
was calculated and standardized using a bootstrap estimate of the variance of the dier-
ence. By comparing these test statistics with quantiles of the standard normal distribution,
p-values were calculated. We see that dierences between lung function and weight as pre-
dictive markers are statistically signicant, no matter what summary index is employed.
Note however that each test relates to a dierent question about predictive performance,
depending on the particular summary index on which it is based. Asking if PEVs for weight
and lung function are equal is not the same as asking if the proportion of subjects whose
risks are less than 0.25, R 1(0:25), are equal. Asking if PEVs for weight and lung function
are equal is not the same as asking if the AUCs for risks associated with weight and FEV1
are equal.
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Next, we randomly sampled 1280 cases and 1280 controls from the entire cohort to form a
nested case-control study sample that is about 1/5 th the size of the cohort. Table 4 presents
results that use data on FEV1 and weight from the case-control subset and the estimate of
the overall incidence of pulmonary exacerbation from the entire cohort, ^ = 0:41. Estimates
of summary indices are very close to the cohort estimates but corresponding condence
intervals are much wider. Nevertheless conclusions remain the same. This demonstrates
that in a study where predictive markers are costly to obtain, the nested case-control design
could yield considerable cost savings.
Predictiveness summary measures, such as R() and R 1(p), are based on a single point
on the predictiveness curve. Others, such as true and false positive rates and event rates,
accumulate dierences over part of the curve. Measures such as PEV, TG and AUC accumu-
late dierences over the entire curve. One might conjecture that measures that accumulate
dierences would often be more powerful for testing if the predictiveness curves are equal.
To investigate, we varied the case-control sample size and evaluated p-values associated with
dierences between the various summary measures. From Table 4, with a reasonably large
case-control sample size (n=2560), we concluded that dierences between almost all sum-
mary indices for the two markers are signicantly dierent. However we see from Table 5
that as the size of the case-control study varies from medium (n=500) to small (n=100), the
point estimates of measures based on specic thresholds become much more variable and
p-values for dierences between lung function and weight become statistically insignicant
in most cases. In contrast, conclusions about the superiority of lung function as a predictive
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marker remained rm when PEV, TG or AUC were used as the basis of hypothesis tests
about equality of curves, even with very small sample sizes (n=100).
8 Concluding Remarks
This paper presents some new clinically relevant measures that quantify the predictive per-
formance of a risk marker. New measures formally dened include TPR(p), FPR(p), PPV(p),
NPV(p), R(T ), R(F ), although several of these are already used informally in the applied
literature. We have previously argued for use of R() and R 1(p) in practice. In addition we
have provided new intuitive interpretations for some existing predictive measures, including
the popular proportion of explained variation, PEV which is called the IDI by Pencina et
al. (2008), the standardized total gain, TG, and recently proposed risk reclassication mea-
sures, namely the NRI and the risk reclassication percent. We demonstrated that all of
these measures are functions of the risk distribution, also known as the predictiveness curve.
A fundamental initial step in the assessment of any risk model is to evaluate if risks calcu-
lated according to the model reect the probabilities P (D = 1jY ). The predictiveness curve
can also be useful in making this assessment (Pepe et al., 2008) and is complemented by
use of the Hosmer-Lemeshow statistic (Hosmer and Lemeshow, 1989). In our cystic brosis
example, the two linear logistic risk models, one for lung function and one for weight, both
yield Hosmer-Lemeshow test p-values>0.05, indicating that they t the observed data well.
A second contribution of this paper is to provide distribution theory for estimators of
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the summary indices. Such has not been available for most of the measures heretofore,
including the popular PEV measure. Our methods can now be used to construct condence
intervals for the summary indices. Simulation studies indicate that the methods are valid
for application in practice with nite samples.
We also demonstrated in an example how summary indices can be used to make formal
rigorous comparisons between markers. Such has only been possible previously for compar-
isons based on the AUC or on point estimates of the predictiveness curve, R() and R 1(p)
(Huang et al., 2007; Huang and Pepe, 2008).
Our methods accommodate cohort or case-control study designs. The latter are par-
ticularly important in the early phases of biomarker development when biomarker assays
are expensive or procurement of biological samples is dicult (Pepe et al., 2001). In such
settings nested case-control studies are much more feasible (Baker et al., 2002; Pepe et al.,
2008d). Our methodology is currently restricted to risk models that include a single marker
or a predened combination of markers. In practice studies often involve development of a
marker combination and assessment of its performance. Compelling arguments have been
provided in the literature for splitting a dataset into training and test subsets (Simon, 2006;
Ransoho, 2004). In these circumstances our methods apply to evaluation with the test data
of the combination developed with the training data. It would be worthwhile however to
explore use of cross validation techniques for simultaneous development and assessment of
risk models using the summary indices we have described.
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Which summary index should be recommended for use in practice? In our opinion, a
summary index should not replace the display of the risk distributions (Figures 1 and 2) but
should serve only to complement them. The choice of summary indices to report should be
driven by the scientic objectives of the study. For example, if the objective is to risk stratify
the population according to some risk threshold, below which treatment is not indicated and
above which treatment is indicated, the corresponding proportions of the population that
fall into the two risk strata, R 1(pL) and 1  R 1(pL) would be key performance measures
to report. Yet additional measures would also be of interest in this setting and should be
reported including TPR(pL), FPR(pL), PPV(pL) and NPV(pL). When no risk thresholds
have been dened as clinically relevant, PEV or TG or AUC could complement the displays of
risk distributions and serve as the basis of test statistics to test for the equality of dierences
between case and control risk distribution curves.
The nal stages of evaluating a model for use in practice should incorporate notions of
costs and benets (i.e. utilities) that may be associated with decisions based on risk(Y ).
However, specifying costs and benets is typically very dicult in practice. Vickers and Elkin
(2006) have recently proposed a standardized measure of expected utility for a prediction
model that does not require explicit specications of costs and benets. The net benet at
risk threshold p is dened as NB(p) = TPR(p)+(1 )FPR(p)p=(1 p), and their decision
curve plots NB(p) versus p. This weighted average of true and false positive rates could
complement descriptive plots of risk distributions. Moreover, the methods for inference that
we have presented here give rise to methods for inference about decision curves too.
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Appendix: Asymptotic Theory
To simplify notation, we suppose the risk model is logistic linear in Y :
logitfG(; Y )g = 0 + 1Y:
I. Cohort Design
In a cohort study the log likelihood function is
l(jY1; :::; Yn) =
nDX
i=1
log
exp(0 + 1Yi)
1 + exp(0 + 1Yi)
+
n DX
i=1
log
1
1 + exp(0 + 1Yi)
: (15)
Let ^0, ^1 be the maximum likelihood estimators (MLE) of 0, 1 based on (15). The following
results are well known.
Result 1 Let
A0(; t) =
Z t
 1
exp(0 + 1y)
(1 + exp(0 + 1y))2
dF (y)
A1(; t) =
Z t
 1
yexp(0 + 1y)
(1 + exp(0 + 1y))2
dF (y)
A2(; t) =
Z t
 1
y2exp(0 + 1y)
(1 + exp(0 + 1y))2
dF (y)
A(; t) =
2
664
A0(; t) A1(; t)
T
A1(; t) A2(; t)
3
775 ;
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and A() = A(;1). If A() 1 exists,
p
n
2
664
^0   0
^1   1
3
775 !d N(0; A() 1):
We can also write
p
n(^   ) = 1p
n
Pn
i=1 `(Yi) + op(1), where `(Yi) = A()
 1 _l(Yi), i =
1; :::; n. And
_l(Yi) =
2
664
@l(jYi)=@0
@l(jYi)=@1
3
775 =
2
664
Di   exp(0 + 1Yi)=(1 + exp(0 + 1Yi))
DiYi   Yiexp(0 + 1Yi)=(1 + exp(0 + 1Yi))
3
775 :
Result 2 As n !1,
p
n(^  ) !d N(0; (1   )),
p
n(F^ (t)  F (t))!d N(0; F (t)(1  F (t))),
p
n(F^D(t)  FD(t)) !d N(0; FD(t)(1  FD(t))=),
p
n(F^ D(t)  F D(t)) !d N(0; F D(t)(1  F D(t))=(1  )),
where   nD=n.
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Lemma 1 Let
BD;0(t) =
Z t
 1
1
1 + exp(0 + 1y)
dFD(y)
BD;1(t) =
Z t
 1
y
1 + exp(0 + 1y)
dFD(y)
B D;0(t) =
Z t
 1
exp(0 + 1y)
1 + exp(0 + 1y)
dF D(y)
B D;1(t) =
Z t
 1
yexp(0 + 1y)
1 + exp(0 + 1y)
dF D(y);
and use BD;0, BD;1, B D;0 and B D;1 for the limits at t = 1.
Then we have
cov(
p
n(^   );pn(F^ (t)  F (t))
=A() 1
2
664
BD;0(t)  (1  )B D;0(t)
BD;1(t)  (1  )B D;1(t)
3
775
cov(
p
n(^   );pn(F^D(t)  FD(t))
=A() 1
2
664
BD;0(t)  FD(t)BD;0
BD;1(t)  FD(t)BD;1
3
775
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cov(
p
n(^   );pn(F^ D(t)  F D(t))
=A() 1
2
664
 B D;0(t) + F D(t)B D;0
 B D;1(t) + F D(t)B D;1
3
775
Proof:
We prove the rst result and proofs of the other two results follow from similar arguments.
cov(
p
n(^   );pn(F^ (t)  F (t))
=cov(
1p
n
nX
i=1
A() 1 _l(Yi);
1p
n
nX
i=1
(I(Yi  t)  F (t)))
=cov(A() 1 _l(Y ); I(Y  t)  F (t)))
=A() 1E( _l(Y ) I(Y  t))
=A() 1fE( _l(YD) I(YD  t)) + (1  )E( _l(Y D) I(Y D  t))g
=A() 1
2
664
BD;0(t)  (1  )B D;0(t)
BD;1(t)  (1  )B D;1(t)
3
775
Proof of Theorem items (i), (ii) and (iii) We show the proof for item (i). The proofs
for items (ii) and (iii) follow similar arguments.
p
n(R^ 1(p)  R 1(p)) = pn(F^ (G 1(^; p))  F (G 1(; p)))
=
p
n(F^ (G 1(; p))   F (G 1(; p))) +pn(F (G 1(^; p))   F (G 1(; p))) + Rn;
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where
Rn =
p
n(F^ (G 1(^; p))  F^ (G 1(; p))) pn(F (G 1(^; p))  F (G 1(; p))) = op(1)
by equicontinuity of the process
p
n(F^   F ). Earlier results and the delta method then
imply:
1(p)
2 =var(
p
n(R^ 1(p)   R 1(p)))
=var(
p
n(F^ (G 1(; p))  F (G 1(; p)))) + var(pn(F (G 1(^; p))  F (G 1(; p))))
+ 2cov
p
n(F^ (G 1(; p))  F (G 1(; p)));pn(F (G 1(^; p))   F (G 1(; p)))) (16)
=R 1(p)(1  R 1(p)) + (@R
 1(p)
@
)TA() 1(
@R 1(p)
@
)
+ 2(
@R 1(p)
@
)TA() 1
2
664
BD;0(G
 1(; p))  (1  )B D;0(G 1(; p))
BD;1(G
 1(; p))  (1  )B D;1(G 1(; p))
3
775 :
The last equality follows from Result 2 (for variance of F^ ), Result 1 (for variance of ^) and
Lemma 1 (for covariance of (F^ ; ^)).
Proof of Theorem items (iv) and (v)
We write
^PPV (p) =
^
1  ^
^TPR(p)
^FPR(p)
;
The asymptotic distribution of
p
n(^   ) is given in Result 2 as are the distributions of
52
http://biostats.bepress.com/uwbiostat/paper342
p
n( ^TPR(p)  TPR(p)) and pn( ^FPR(p)   FPR(p)) because:
p
n( ^TPR(p)   TPR(p)) =pn((1  F^D(G 1(^; p)))  (1  FD(G 1(; p))))
= pn(F^D(G 1(^; p))   FD(G 1(; p))):
And similarly,
p
n( ^FPR(p)   FPR(p)) =  pn(F^ D(G 1(^; p))   F D(G 1(; p))):
In the following, we calculate the covariances between (
p
n( ^TPR(p) TPR(p));pn(^  )),
(
p
n( ^FPR(p) FPR(p));pn(^ )) and (pn( ^TPR(p) TPR(p));pn( ^FPR(p) FPR(p))).
The asymptotic variance of
p
n( ^PPV (p)   PPV (p)), 4(p)2, then follows from the delta
method.
Consider the covariance between
p
n( ^TPR(p)   TPR(p)) and pn( ^FPR(p)  FPR(p)):
cov1 =cov(
p
n( ^TPR(p)  TPR(p));pn( ^FPR(p)   FPR(p)))
=cov(
p
n(F^D(G
 1(^; p))  FD(G 1(; p)));
p
n(F^ D(G
 1(^; p))   F D(G 1(; p))))
=cov(
p
n(F^D(G
 1(; p))  FD(G 1(; p))) +
p
n(FD(G
 1(^; p))  FD(G 1(; p))) + op(1);
p
n(F^ D(G
 1(; p))   F D(G 1(; p))) +
p
n(F D(G
 1(^; p))  F D(G 1(; p))) + op(1));
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Because F^D and F^ D are uncorrelated, the above covariance can be written as
cov1 =cov(
p
n(FD(G
 1(^; p))  FD(G 1(; p)));
p
n(F D(G
 1(^; p))   F D(G 1(; p))))
+ cov(
p
n(F^ D(G
 1(; p))  F D(G 1(; p)));
p
n(FD(G
 1(^; p))   FD(G 1(; p))))
+ cov(
p
n(F^D(G
 1(; p))  FD(G 1(; p)));
p
n(F D(G
 1(^; p))   F D(G 1(; p))))
=(
@TPR(p)
@
)T var(
p
n(^   ))(@FPR(p)
@
)
  (@TPR(p)
@
)T cov(
p
n(F^ D(G
 1(; p))   F D(G 1(; p)));
p
n(^   ))
  (@FPR(p)
@
)T cov(
p
n(F^D(G
 1(; p))   FD(G 1(; p)));
p
n(^   )) (17)
=(
@TPR(p)
@
)TA() 1(
@FPR(p)
@
)
  (@TPR(p)
@
)TA() 1
2
664
 B D;0(G 1(; p)) + (1  FPR(p))B D;0
 B D;1(G 1(; p)) + (1  FPR(p))B D;1
3
775
  (@FPR(p)
@
)TA() 1
2
664
BD;0(G
 1(; p))  (1  TPR(p))BD;0
BD;1(G
 1(; p))  (1  TPR(p))BD;1
3
775 (18)
The last equality uses Result 1 (for variance of ^) and Lemma 1 (for covariance of (F^D; ^)
and (F^ D; ^)).
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The second covariance (equation (10)) is between
p
n(^  ) and pn( ^TPR(p)   TPR(p)):
cov2 =cov(
p
n(^  );pn( ^TPR(p)  TPR(p)))
=  cov(pn(^  );pn(F^D(G 1(; p))  FD(G 1(; p))) +
p
n(FD(G
 1(^; p))   FD(G 1(; p))))
=  cov(pn(^  );pn(FD(G 1(^; p))  FD(G 1(; p))))
 cov(pn(^  );pn(F^D(G 1(; p))  FD(G 1(; p))))
  (An + Bn);
where An = cov(
p
n(^   );pn(FD(G 1(^; p))   FD(G 1(; p)))) and Bn = cov(
p
n(^  
);
p
n(F^D(G
 1(; p))  FD(G 1(; p)))).
Observe that
p
n(^  ) = pn(
Z
G(^; Y )dF^ (Y ) 
Z
G(; Y )dF (Y ))
=
p
n(
Z
(G(^; Y ) G(; Y ))dF (Y ) +pn
Z
G(; Y )d(F^ (Y )  F (Y )) + Hn
=(
Z
@R()
@
d)
p
n(^   ) +pn
Z
G(; Y )d(F^ (Y )  F (Y )) + Hn;
where R()  G(; Y ) and Hn  pn
R
(G(^; Y ) G(; Y ))d(F^ (Y ) F (Y )) = 1p
n
R p
n(G(^; Y ) 
G(; Y ))d(
p
n(F^ (Y )   F (Y ))). Both pn(G(^; Y )   G(; Y )) and pn(F^ (Y )   F (Y )) are
bounded in probability and therefore Hn converges to 0 as n !1.
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We next derive expressions for An and Bn.
An =cov(
p
n(^  );pn(FD(G 1(^; p))  FD(G 1(; p))))
=(
@(1  TPR(p))
@
)T cov(
p
n(^  );pn(^   ))
=(
@(1  TPR(p))
@
)Tfvar(pn(^   ))
Z
@R()
@
d + cov(
p
n
Z
G(; Y )d(F^ (Y )   F (Y ));pn(^   ))g
=(
@(1  TPR(p))
@
)Tfvar(pn(^   ))
Z
@R()
@
d + cov(1=
p
n
nX
i=1
G(; Yi); 1=
p
n
nX
i=1
A() 1 _l(Yi))g
=(
@(1  TPR(p))
@
)TA() 1(
Z
@R()
@
d) + (
@(1  TPR(p))
@
)A() 1cov(G(; Y ); _l(Y ))
=(
@(1  TPR(p))
@
)TA() 1(
Z
@R()
@
d)
+(
@(1  TPR(p))
@
)TA() 1
2
664

R
G(;y)
1+exp(0+1y)
dFD(y) + (1  )
R  G(;Y )exp(0+1y)
1+exp(0+1y)
dF D(y)

R
yG(;y)
1+exp(0+1y)
dFD(y) + (1  )
R  yG(;Y )exp(0+1y)
1+exp(0+1y)
dF D(y)
3
775
(19)
And Bn is
Bn =cov(
p
n(^   );pn(F^D(G 1(; p))   FD(G 1(; p))))
=(
Z
@R()
@
d)T cov(
p
n(^   );pn(F^D(G 1(; p))   FD(G 1(; p))))
cov(
Z
G(; Y )d(
p
n(F^ (Y )  F (Y ));pn(F^D(G 1(; p))  FD(G 1(; p))))
=(
Z
@R()
@
d)T cov(
p
n(^   );pn(F^D(G 1(; p))   FD(G 1(; p))))
+ cov(1=
p
n
nX
i=1
G(; Yi);
p
n=nD
nDX
i=1
I(YDi  G 1(; p)))
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=(
Z
@R()
@
d)T cov(
p
n(^   );pn(F^D(G 1(; p))  FD(G 1(; p))))
+ (
Z G 1(;p)
 1
G(; Y )dFD(Y )   FD(G 1(; p))
Z
G(; Y )dFD(Y )); (20)
where cov(
p
n(^   );pn(F^D(G 1(; p))  FD(G 1(; p)))) is given by Lemma 1.
Combining the two terms yields a value for cov2. The derivation of cov3 follows from a similar
argument.
The proof of item (v) of the Theorem uses exactly the same techniques.
Proof of Theorem items (vi), (vii) and (viii) We prove Theorem item (vii) in the
following. Proofs of (vi) and (viii) are similar. The following proof is based on Huang and
Pepe (2008a) where they derived the asymptotic distribution of
p
n(R^() R()) when R()
is estimated under a case-control design.
When the value of TPR is 1  T (t), by a Taylor series expansion,
p
n(R^(T (t))  R(T (t))) =
p
n(G(^; F^ 1D (T (t))) G(; F 1D (T (t))))
=(
@G(; F 1D (T (t)))
@F 1D (T (t))
)
p
n(F^ 1D (T (t))  F 1D (T (t))) + (
@G(; F 1(T (t)))
@
)T
p
n(^   ) + op(1)
=  (@R(T (t))
@t
)
p
n(F^D(F
 1
D (T (t)))  t) + (
@R(T (t))
@
)T
p
n(^   ) + op(1)
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It follows that the asymptotic variance is
7(t)
2 =var(
p
n(R^(T (t))  R(T (t))))
=(
@R(T (t))
@t
)2var(
p
n(F^D(F
 1
D (T (t)))  t)) + (
@R(T (t))
@t
)Tvar(
p
n(^   ))(@R(T (t))
@
)
  2(@R(T (t))
@t
)cov(
p
n(^   );pn(F^D(F 1D (T (t)))  t))(
@R(T (t))
@
): (21)
The variance of
p
n(^ ) and of pn(F^D(F 1D (T (t))) t) are provided in Result 2, and their
covariance is provided in Lemma 1. Putting them all together, we have the following result,
7(t)
2 =(
@R(T (t))
@t
)2T (t)(1  T (t))= + (@R(T (t))
@
)TA() 1(
@R(T (t))
@
)
  2(@R(T (t))
@t
)(
@R(T (t))
@
)TA() 1
2
664
BD;0(F
 1
D (T (t)))  T (t)B D;0(F 1D (T (t)))
BD;1(F
 1
D (T (t)))  T (t)B D;1(F 1D (T (t)))
3
775
Proof of Theorem item (ix)
p
n( ^PEV   PEV )
=
p
nf(
Z
G(^; Y )dF^D  
Z
G(^; Y )dF^ D)  (
Z
G(; Y )dFD  
Z
G(; Y )dF D)g
=
p
nf(
Z
G(^; Y )dF^D  
Z
G(; Y )dFD)  (
Z
G(^; Y )dF^ D  
Z
G(; Y )dF D)g
=fpn(
Z
G(; Y )d(F^D   FD)) +
p
n(
Z
(G(^; Y ) G(; Y ))dFD)g
  fpn(
Z
G(; Y )d(F^ D   F D)) +
p
n(
Z
(G(^; Y ) G(; Y ))dF D)g+ Pn
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(An + Bn)  (Cn + Dn) + Pn;
where Pn =
p
n
R
(G(^; Y ) G(; Y ))d(F^D  FD) +
p
n
R
(G(^; Y ) G(; Y ))d(F^ D   F D). It
is easy to see that Pn converges to zero as n !1 since
p
n(G(^; Y ) G(; Y )) is bounded
in probability and F^D   FD (or F^ D   F D) converges in probability to 0. We dene An 
p
n(
R
G(; Y )d(F^D FD)), Bn  pn(
R
(G(^; Y ) G(; Y ))dFD), Cn  pn(
R
G(; Y )d(F^ D 
F D)) and Dn 
p
n(
R
(G(^; Y ) G(; Y ))dF D).
Now we have,
var(An + Bn) = var(An) + var(Bn) + 2cov(An; Bn)
=var(
1p

1p
nD
nDX
i=1
G(; YDi)) + var((
Z
@G(; Y )
@
dFD(Y ))
T
p
n(^   ))
+ 2(
Z
@G(; Y )
@
dFD(Y ))
T cov(
p
n(
Z
G(; Y )d(F^D   FD));
p
n(^   ))
=var(G(; YD))= + (
Z
@G(; Y )
@
dFD(Y ))
TA() 1(
Z
@G(; Y )
@
dFD(Y ))
+ 2(
Z
@G(; Y )
@
dFD(Y ))
T cov(G(; YD); A()
 1 _l(YD))
=var(G(; YD))= + (
Z
@G(; Y )
@
dFD(Y ))
TA() 1(
Z
@G(; Y )
@
dFD(Y ))
+ 2(
Z
@G(; Y )
@
dFD(Y ))
TA() 1
2
664
P1
P2
3
775 ; (22)
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where
2
664
P1
P2
3
775 
2
664
R
G(; Y )(@l(jYD)=@0)dFD(Y ) 
R
G(; Y )dFD(Y )
R
(@l(jYD)=@0)dFD(Y )
R
G(; Y )(@l(jYD)=@1)dFD(Y ) 
R
G(; Y )dFD(Y )
R
(@l(jYD)=@0)dFD(Y )
3
775
=
2
664
R
G(;Y )
1+exp(0+1Y )
dFD(Y ) 
R
G(; Y )dFD(Y )
R
1
1+exp(0+1Y )
dFD(Y )
R
Y G(;Y )
1+exp(0+1Y )
dFD(Y ) 
R
G(; Y )dFD(Y )
R
Y
1+exp(0+1Y )
dFD(Y )
3
775 : (23)
From a similar argument,
var(Cn + Dn) = var(Cn) + var(Dn) + 2cov(Cn; Dn)
=var(G(; Y D))=(1  ) + (
Z
@G(; Y )
@
dF D)
TA() 1(
Z
@G(; Y )
@
dF D)
+ 2(
Z
@G(; Y )
@
dF D)
TA() 1
2
664
Q1
Q2
3
775 ; (24)
where
2
664
Q1
Q2
3
775 
2
664
  R G(; Y )(@l(jY D)=@0)dF D(Y ) + R G(; Y )dF D(Y ) R (@l(jY D)=@0)dF D(Y )
  R G(; Y )(@l(jY D)=@1)dF D(Y ) + R G(; Y )dF D(Y ) R (@l(jY D)=@1)dF D(Y )
3
775
=
2
664
  R G(;Y )exp(0+1Y )
1+exp(0+1Y )
dF D(Y ) +
R
G(; Y )dF D(Y )
R
exp(0+1Y )
1+exp(0+1Y )
dF D(Y )
  R Y G(;Y )exp(0+1Y )
1+exp(0+1Y )
dF D(Y ) +
R
G(; Y )dF D(Y )
R
Y exp(0+1Y )
1+exp(0+1Y )
dF D(Y )
3
775 : (25)
Because F^D and F^ D are independent the covariance between An and Cn is zero. Observe
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also that from previous derivations we have
cov(An + Bn; Cn + Dn) = cov(An; Dn) + cov(Bn; Cn) + cov(Bn; Dn)
=(
Z
@G(; Y )
@
dFD)
TA() 1(
Z
@G(; Y )
@
dF D)
+ (
Z
@G(; Y )
@
dFD)
TA() 1
2
664
Q1
Q2
3
775 + (
Z
@G(; Y )
@
dF D)
TA() 1
2
664
P1
P2
3
775 (26)
The asymptotic variance of
p
n( ^PEV  PEV ), 29, can be obtained by combining var(An +
Bn), var(Cn + Dn) and cov(An + Bn; Cn + Dn).
Proof of Theorem item (x)
p
n( ^TG  TG) = pnf( ^TPR(^)  ^FPR(^))  (TPR()  FPR())g
=
p
n( ^TPR(^)  TPR()) pn( ^FPR(^)  FPR()):
The result in the Theorem follows. Now we derive expressions for the variance components
in a cohort study. Observe that
 pn( ^TPR(^)  TPR())
=
p
n(F^D(G
 1(^; ^))  FD(G 1(; )))
=
p
n(F^D(G
 1(^; ^))  F^D(G 1(; ))) 
p
n(FD(G
 1(^; ^))  FD(G 1(; )))
+
p
n(F^D(G
 1(; ))  FD(G 1(; ))) +
p
n(FD(G
 1(^; ^))  FD(G 1(; )))
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=
p
n(F^D(G
 1(; ))  FD(G 1(; ))) + fD(G 1(; ))@G
 1(; )
@
p
n(^   )
+ fD(G
 1(; ))
@G 1(; )
@
p
n(^  ) + op(1)
An + Bn + Cn + op(1);
where we dene
An 
p
n(F^D(G
 1(; ))  FD(G 1(; )));
Bn  fD(G 1(; ))@G
 1(; )
@
p
n(^   );
Cn  fD(G 1(; ))@G
 1(; )
@
p
n(^  ):
and note that
p
n(F^D(G
 1(^; ^))  F^D(G 1(; ))) 
p
n(FD(G
 1(^; ^)) FD(G 1(; ))) ! 0
as n !1 due to the equicontinuity of the process.
1 var(
p
n( ^TPR(^)  TPR()))
=var(An) + var(Bn) + var(Cn) + cov(An; Bn) + cov(An; Cn) + cov(Bn; Cn) (27)
The variance of Bn follows from that of
p
n(^   ) given in Result 1, and the variances of
An and Cn both follow from Result 2. cov(An; Bn) follows from Lemma 1. Furthermore,
cov(An; Cn) and cov(Bn; Cn) concern the covariance between (F^D; ^) and (^; ^), both of which
can be found in the proof of Theorem item (iv), cov2 (see equation (19) and (20)).
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Similarly, we have
 pn( ^FPR(^)  FPR())
=
p
n(F^ D(G
 1(^; ^))  F D(G 1(; )))
=
p
n(F^ D(G
 1(; ))  F D(G 1(; ))) + f D(G 1(; ))
@G 1(; )
@
p
n(^   )
+ f D(G
 1(; ))
@G 1(; )
@
p
n(^  ) + op(1)
Dn + En + Fn + op(1): (28)
The variance of
p
n( ^FPR(^)  FPR()), 2 (equation (13)), depends on the variances and
covariances of the three terms
Dn 
p
n(F^ D(G
 1(; ))  F D(G 1(; )));
En f D(G 1(; ))
@G 1(; )
@
p
n(^   );
Fn f D(G 1(; ))
@G 1(; )
@
p
n(^  ):
The variance of En can be obtained by using Result 1, and the variances of Dn and Fn
can be found using Result 2. The covariance between Dn and En follows from Lemma 1.
Covariances between (Dn; Fn) and (En; Fn) follow from an argument similar to that used in
deriving cov(An; Cn) and cov(Bn; Cn) (equation (19) and (20)).
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The asymptotic variance of
p
n( ^TG  TG), 210, is therefore
210 = 1 + 2   21;2;
where 1;2 is
1;2 cov(
p
n( ^TPR(^)  TPR());pn( ^FPR(^)  FPR()))
=cov(An + Bn + Cn; Dn + En + Fn)
=cov(An; En) + cov(An; Fn) + cov(Bn; Dn) + cov(Bn; En) + cov(Bn; Fn)
+cov(Cn; Dn) + cov(Cn; En) + cov(Cn; Fn): (29)
All of these covariance terms can be obtained using corresponding Results and Lemmas:
cov(An; En) and cov(Bn; Dn) from Lemma 1; cov(Bn; En) from Result 1; cov(Cn; Fn) from
Result 2. cov(An; Fn) and cov(Bn; Fn) concern the covariance between (F^D; ^) and (^; ^) and
expressions have been derived in the proof of Theorem item (iv) above, cov2 (equation (19)
and (20)), while cov(Cn; Dn) and cov(Cn; En) concern the covariance between (F^ D; ^) and
(^; ^) and are derived using a similar argument.
II. Case-Control Design
Let ^ be the estimate of disease prevalence  from a cohort independent of the case-control
sample, or the parent cohort within which the case-control sample is nested. Assume the
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size of the cohort is  times the size of the case-control sample. Denote
F^ (t) = F^D(t) + (1  )F^ D(t)
^ =
2
664
^0
^1
3
775 =
2
664
^0s + log(
n D
nD

1 )
^1s
3
775 :
The following results are well established.
Result 3 Let
A0(t) =
Z t
 1
exp(0 + 

1y)
(1 + kexp(0 + 

1y))
dF D(y)
A1(t) =
Z t
 1
yexp(0 + 

1y)
(1 + kexp(0 + 

1y))
dF D(y)
A2(t) =
Z t
 1
y2exp(0 + 

1y)
(1 + kexp(0 + 

1y))
dF D(y)
A(t) =
2
664
A0(t) A1(t)
T
A1(t) A2(t)
3
775 ;
where k  nD=n D and A = A(1). If A 1 exists,
p
n
2
664
^0   0
^1   1
3
775 !d N(0; 1);
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where
 =
1 + k
k
fA 1  
2
664
1 + k 0
0 0
3
775g:
A proof can be found in Prentice and Pyke (1979), Qin and Zhang (1997) and Zhang (2000).
The next set of results, Results 4-7, have been proved by Huang and Pepe (2008a).
Result 4 As n ! 1, pn(F^ (t)   F (t)) converges to a normal random variable with
mean 0 and variance
2F = (1  )2(1 + k)F D(t)(1  F D(t)) + 2
1 + k
k
FD(t)(1  FD(t)):
Result 5
cov(
p
n(^   );pn(F^D(t)  FD(t))) = n
nD
fA 1
2
664
A0(t)
A1(t)
3
775  
2
664
FD(t)
0
3
775g;
cov(
p
n(^   );pn(F^ D(t)  F D(t))) =
n
n D
f A 1
2
664
A0(t)
A1(t)
3
775 +
2
664
F D(t)
0
3
775g
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cov(
p
n(^   );pn(F^ (t)  F (t))) = n
n D
(1  )f A 1
2
664
A0(t)
A1(t)
3
775 +
2
664
F D(t)
0
3
775g
+
n
nD
fA 1
2
664
A0(t)
A1(t)
3
775 
2
664
FD(t)
0
3
775g:
Result 6
var(
p
n(^  )) = (1  )=;
var(
p
n(^   )) =
2
664
1
(1 ) 0
0 0
3
775 + var(
p
n(^   ));
cov(
p
n(^   );
p
(^  )) =
2
664
1=
0
3
775 :
Result 7
var(
p
n(F^ (t)  F (t))) = (FD(t)  F D(t))2(1  )= + var(
p
n(F^ (t)  F (t)));
cov(
p
n(^   );pn(F^ (t)  F (t))) =
2
664
FD(t) F D(t)

0
3
775 + cov(
p
n(^   );pn(F^ (t)  F (t)));
cov(
p
n(^   );pn(F^D(t)  FD(t))) = cov(
p
n(^   );pn(F^D(t)  FD(t)));
cov(
p
n(^   );pn(F^ D(t)  F D(t))) = cov(
p
n(^   );pn(F^ D(t)  F D(t))):
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Most of the proofs in the following are exactly the same as those developed for a cohort
study. Therefore we do not repeat the proofs that are the same. However, expressions for
the components of the asymptotic variances that are dierent are provided. We will fre-
quently refer to expressions in Results 4-7.
Proof of Theorem item (i), (ii) and (iii)
The proof is the same as the proof provided for cohort studies. Based on equation (16),
1(p)
2 =var(
p
n(F^ (G 1(; p))   F (G 1(; p)))) + (@R
 1(p)
@
)T var(
p
n(^   ))(@R
 1(p)
@
)
+2(
@R 1(p)
@
)T cov(
p
n(^   );pn(F^ (G 1(; p))  F (G 1(; p)))):
Expressions for the three individual components can all be found in Results 6 and 7. Proofs
for items (ii) and (iii) of the Theorem follow similar arguments.
Proof of Theorem items (iv) and (v)
According to equation (17),
cov1 =(
@TPR(p)
@
)T var(
p
n(^   ))(@FPR(p)
@
)
  (@TPR(p)
@
)T cov(
p
n(F^ D(G
 1(; p))   F D(G 1(; p)));
p
n(^   ))
  (@FPR(p)
@
)T cov(
p
n(F^D(G
 1(; p))   FD(G 1(; p)));
p
n(^   )):
Results 6 and 7 provide expressions for the three individual terms.
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However, the expressions for cov2 and cov3 are dierent from those under a cohort study
design,
cov2 =cov(
p
n( ^TPR(p)  TPR(p));pn(^  ))
=  cov(pn(F^D(G 1(^; p))  FD(G 1(; p)));
p
n(^  ))
=  cov(pn(F^D(G 1(; p))  FD(G 1(; p))) +
p
n(FD(G
 1(^; p))  FD(G 1(; p)));
p
n(^  ))
=  cov(pn(FD(G 1(^; p))  FD(G 1(; p)));
p
n(^  ))
=(
@TPR(p)
@
)T 
2
664
1=
0
3
775
Similarly,
cov3 =cov(
p
n( ^FPR(p)  FPR(p));pn(^  ))
=  cov(pn(F^ D(G 1(^; p))  F D(G 1(; p)));
p
n(^  ))
=(
@FPR(p)
@
)T 
2
664
1=
0
3
775
Item (v) of the Theorem follows from a similar argument.
Proof of Theorem (vi), (vii) and (viii) These all follow similar arguments. We use
(vii) to illustrate.
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According to equation (21),
7(t)
2 =var(
p
n(R^(T (t))  R(T (t))))
=(
@R(T (t))
@t
)2var(
p
n(F^D(F
 1
D (T (t)))  t)) + (
@R(T (t))
@t
)Tvar(
p
n(^   ))(@R(T (t))
@
)
  2(@R(T (t))
@t
)cov(
p
n(^   );pn(F^D(F 1D (T (t)))  t))(
@R(T (t))
@
):
The result follows by plugging in corresponding expressions from Result 2, 6 and 7. Proofs
of items (vi) and (viii) follow similar arguments.
Proof of Theorem item (ix) Proof of Theorem (ix) is exactly the same as the proofs
for a cohort study. Equations (22), (24) and (26) dened expressions for the components of
the asymptotic variance of
p
n( ^PEV   PEV ), 29. We only need to substitute l() in the
denition of
2
664
P1
P2
3
775 and
2
664
Q1
Q2
3
775 (equation (23) and (25)) with the likelihood function based
on case-control data, which are dened by Prentice and Pyke (1979), Qin and Zhang (1997)
and Zhang (2000).
Proof of Theorem item (x) According to equations (27), (28) and (29), the three com-
ponents of var(
p
n( ^TG  TG)), 210, are
1 =var(An) + var(Bn) + var(Cn) + cov(An; Bn) + cov(An; Cn) + cov(Bn; Cn);
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2 =var(Dn) + var(En) + var(Fn) + cov(Dn; En) + cov(Dn; Fn) + cov(En; Fn);
1;2 =cov(An; En) + cov(An; Fn) + cov(Bn; Dn) + cov(Bn; En) + cov(Bn; Fn)
+cov(Cn; Dn) + cov(Cn; En) + cov(Cn; Fn):
The following Results provide corresponding expressions for each of the individual compo-
nents:
Result 2: var(An) and var(Dn).
Result 3: cov(Bn; En).
Result 6: var(Bn), var(Cn), var(En), cov(Bn; Cn), var(Fn), cov(En; Fn), cov(Bn; Fn), cov(Cn; En)
and cov(Cn; Fn).
Result 7: cov(An; Bn), cov(Dn; En), cov(Bn; Dn) and cov(An; En).
Furthermore, cov(An; Cn)=cov(Dn; Fn)=cov(An; Fn)=cov(Cn; Dn)=0.
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Table 1: Results of simulations to evaluate the application of inference based on asymptotic distribution theory and bootstrap resampling to finite 
sample studies. The study employs cohort design with prevalence 0.2. Marker data for controls are standard normally distributed and for cases is 
normally distributed with mean 1 and variance 1. Shown are results for R(v), R
-1
(p), R(v(TPR)) and R(v(FPR)). 
 
  v=0.1 v=0.5 v=0.9 p=0.1 p=0.35 p=0.6 TPR=.9 TPR=.5 TPR=.1 FPR=.9 FPR=.5 FPR=.1 
   R(v)=   R
-1
(p)=  R(v(TPR))= R(v(FPR))= 
  0.045 0.154 0.427 0.321 0.839 0.972 0.103 0.292 0.598 0.040 0.132 0.353 
% Bias 
n=100  7.15 -1.56  -0.26 3.47 -0.08 -0.85 15.84 5.77 -3.30 11.17 -2.75 -3.43 
n=500  1.59 0.06 -0.14 0.62 0.04 -0.18 2.95 0.89 -0.78 2.80 -0.25 -0.60 
n=2000  0.21 -0.24 0.09 0.04 0.02 -0.04 0.84 0.30 -0.32 0.79 -0.10 -0.14 
Standard deviation 
n=100 observed 
asymptotic 
bootstrap 
0.027 
0.027 
0.028 
0.045 
0.044 
0.044 
0.104 
0.100 
0.104 
0.142 
0.136 
0.140 
0.074 
0.077 
0.084 
0.033 
0.037 
0.050 
0.037 
0.036 
0.041 
0.086 
0.089 
0.092 
0.153 
0.154 
0.152 
0.028 
0.026 
0.027 
0.043 
0.041 
0.037 
0.068 
0.065 
0.064 
n=500 observed 
asymptotic 
bootstrap 
0.013 
0.012 
0.012 
0.021 
0.020 
0.020 
0.044 
0.045 
0.046 
0.064 
0.063 
0.065 
0.035 
0.035 
0.035 
0.015 
0.016 
0.016 
0.016 
0.016 
0.017 
0.037 
0.038 
0.038 
0.072 
0.072 
0.073 
0.012 
0.012 
0.013 
0.019 
0.019 
0.018 
0.029 
0.029 
0.028 
n=2000 observed 
asymptotic 
bootstrap 
0.006 
0.006 
0.006 
0.010 
0.010 
0.010 
0.023 
0.023 
0.023 
0.032 
0.032 
0.032 
0.017 
0.018 
0.018 
0.008 
0.008 
0.008 
0.008 
0.008 
0.008 
0.018 
0.019 
0.019 
0.038 
0.037 
0.037 
0.006 
0.006 
0.006 
0.009 
0.009 
0.009 
0.015 
0.015 
0.016 
95% coverage probability 
n=100 asymptotic 
bootstrapN  
bootstrapP  
88.7 
89.4 
92.0 
93.0 
91.4 
93.0 
92.1 
95.0 
96.2 
89.6 
90.2 
92.6 
92.8 
95.4 
96.0 
90.0 
96.8 
96.0 
94.8 
98.2 
96.8 
93.7 
96.4 
97.6 
87.2 
88.8 
93.4 
87.6 
89.3 
93.8 
92.7 
90.6 
93.4 
93.9 
92.5 
95.8 
n=500 asymptotic 
bootstrapN  
bootstrapP  
94.0 
93.8 
95.0 
94.6 
94.8 
94.4 
94.4 
94.8 
94.2 
93.2 
94.8 
95.6 
94.7 
95.8 
95.6 
93.1 
91.8 
95.0 
94.5 
96.4 
97.2 
94.7 
95.8 
95.8 
92.4 
94.0 
95.8 
93.9 
94.2 
93.6 
94.5 
92.8 
96.8 
94.4 
94.8 
95.4 
n=2000 asymptotic 
bootstrapN  
bootstrapP  
94.9 
95.0 
93.8 
95.4 
96.2 
96.2 
95.2 
95.6 
95.0 
94.4 
94.2 
95.0 
94.7 
94.6 
94.4 
95.2 
94.6 
95.0 
94.8 
96.0 
95.6 
95.0 
94.8 
94.8 
94.3 
96.0 
95.6 
94.7 
94.8 
95.0 
95.2 
94.8 
94.6 
94.6 
95.2 
94.6 
 
* bootstrap-N: confidence intervals are based on the normal assumption of bootstrapped values 
      bootstrap-P: confidence intervals are based on percentile of bootstrapped values 
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Table 2: Results of simulations to evaluate the application of inference based on asymptotic distribution theory and bootstrap resampling to finite 
sample studies. Data were generated as described for Table 1. Shown are results for TPR(p), FPR(p), PPV(p) and NPV(p).  
 
  p=0.1 p=0.35 p=0.6 p=0.1 p=0.35 p=0.6 p=0.1 p=0.35 p=0.6 p=0.1 p=0.35 p=0.6 
  TPR(p)= FPR(p)= PPV(p)= NPV(p)= 
  0.905 0.395 0.098 0.622 0.103 0.011 0.267 0.490 0.691 0.941 0.856 0.814 
% Bias 
n=100  -0.20 -1.09 29.45 -1.48 -0.21 18.82 3.53 -0.05 -14.08 -0.75 0.42 0.73 
n=500  0.01 -0.89 5.48 -0.10 -0.58 3.69 0.70 -0.02 -1.88 0.03 0.08 0.15 
n=2000  0.01 0.05 1.12 0.02 -0.05 1.83 0.04 -0.05 -0.19 0.02 0.02 0.06 
Standard deviation 
n=100 observed 
asymptotic 
bootstrap 
0.074 
0.073 
0.092 
0.174 
0.161 
0.168 
0.116 
0.117 
0.128 
0.158 
0.151 
0.154 
0.052 
0.054 
0.067 
0.016 
0.019 
0.033 
0.053 
0.052 
0.052 
0.115 
0.117 
0.117 
0.211 
0.213 
0.210 
0.045 
0.045 
0.045 
0.032 
0.033 
0.030 
0.037 
0.036 
0.034 
n=500 observed 
asymptotic 
bootstrap 
0.029 
0.030 
0.032 
0.077 
0.075 
0.078 
0.054 
0.054 
0.053 
0.073 
0.071 
0.072 
0.023 
0.024 
0.024 
0.007 
0.008 
0.007 
0.022 
0.022 
0.021 
0.042 
0.041 
0.040 
0.135 
0.132 
0.136 
0.015 
0.015 
0.016 
0.014 
0.015 
0.014 
0.016 
0.016 
0.016 
n=2000 observed 
asymptotic 
bootstrap 
0.015 
0.015 
0.015 
0.038 
0.038 
0.039 
0.027 
0.027 
0.027 
0.037 
0.036 
0.037 
0.012 
0.012 
0.012 
0.003 
0.004 
0.004 
0.011 
0.011 
0.011 
0.199 
0.020 
0.020 
0.058 
0.057 
0.056 
0.007 
0.007 
0.007 
0.008 
0.007 
0.007 
0.008 
0.008 
0.008 
95% coverage probability 
n=100 asymptotic 
bootstrapN  
bootstrapP  
93.0 
95.2 
98.0 
90.2 
93.0 
97.0 
87.6 
95.2 
96.8 
88.3 
90.6 
94.8 
93.5 
97.2 
98.2 
91.1 
98.2 
98.6 
95.2 
94.8 
95.0 
96.5 
96.6 
96.6 
96.4 
94.6 
95.0 
91.2 
90.4 
92.4 
93.0 
92.4 
93.4 
93.2 
92.3 
93.5 
n=500 asymptotic 
bootstrapN  
bootstrapP  
93.3 
96.2 
97.4 
93.8 
94.4 
95.0 
91.9 
93.6 
96.2 
93.3 
95.2 
95.8 
94.9 
94.6 
94.8 
93.8 
93.6 
97.0 
94.6 
94.0 
94.0 
95.1 
94.0 
95.4 
96.4 
95.9 
95.2 
92.8 
93.6 
94.8 
94.6 
92.4 
93.2 
95.0 
94.3 
95.1 
n=2000 asymptotic 
bootstrapN  
bootstrapP  
94.7 
94.8 
95.8 
94.9 
96.0 
96.0 
94.2 
93.8 
94.4 
94.4 
93.6 
94.4 
94.9 
95.0 
94.4 
95.3 
94.6 
95.2 
94.7 
95.2 
95.0 
94.7 
95.1 
94.8 
96.0 
95.3 
95.8 
94.6 
95.1 
94.6 
95.1 
95.1 
95.2 
94.6 
93.8 
94.7 
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Table 3: Results of simulations to evaluate the application of inference based on asymptotic 
distribution theory and bootstrap resampling to finite sample studies. Data were generated as 
described for Table 1. Shown are results for PEV, standardized total gain, TG  and AUC. 
 
  PEV=0.154 TG =0.383 AUC=0.760 
% Bias 
n=100  2.68 1.42 0.25 
n=500  1.24 0.48 0.16 
n=2000  -0.05 -0.02 0.02 
Standard deviation 
n=100 observed 
asymptotic 
Bootstrap 
0.078 
0.076 
0.078 
0.105 
0.120 
0.123 
0.061 
0.060 
0.058 
n=500 observed 
asymptotic 
bootstrap 
0.034 
0.034 
0.034 
0.048 
0.051 
0.053 
0.027 
0.026 
0.028 
n=2000 observed 
asymptotic 
bootstrap 
0.018 
0.017 
0.017 
0.025 
0.026 
0.026 
0.013 
0.013 
0.014 
95% coverage probability 
n=100 asymptotic 
bootstrapN 
bootstrapP 
91.8 
90.8 
93.4 
95.1 
96.8 
96.4 
92.5 
94.3 
93.6 
n=500 asymptotic 
bootstrapN 
bootstrapP 
93.9 
93.4 
93.6 
95.2 
95.8 
95.8 
94.4 
95.1 
94.7 
n=2000 asymptotic 
bootstrapN 
bootstrapP 
94.7 
95.4 
95.0 
95.5 
95.3 
95.6 
96.2 
95.7 
96.0 
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Table 4: Results of simulations to evaluate the application of inference based on asymptotic distribution theory and bootstrap 
resampling to finite sample studies. The study design employs case-control sampling from a parent cohort with prevalence 0.2. Marker 
data for controls are standard normally distributed and for cases is normally distributed with mean 1 and variance 1. The case-control 
subset is 1/5 the size of the parent cohort and is randomly selected. Shown are results for R(v), R
-1
(p), R(v(TPR)) and R(v(FPR)).  
 
  v=0.1 v=0.5 v=0.9 p=0.1 p=0.35 p=0.6 TPR=.9 TPR=.5 TPR=.1 FPR=.9 FPR=.5 FPR=.1 
   R(v)=   R
-1
(p)=  R(v(TPR))= R(v(FPR))= 
  0.045 0.154 0.427 0.321 0.839 0.972 0.103 0.292 0.598 0.040 0.132 0.353 
% Bias 
n=100  3.39 -1.55 0.86 0.72 0.35 -0.50 6.63 4.11 -0.19 8.72 -1.59 -3.77 
n=500  0.55 -0.29 0.38 0.35 0.03 -0.07 1.31 0.78 -0.08 1.95 -0.52 -0.72 
n=2000  0.09 -0.06 0.14 0.04 0.01 -0.02 0.37 0.17 0.01 0.67 -0.06 -0.19 
Standard deviation 
n=100 observed 
asymptotic 
bootstrap 
0.022 
0.021 
0.020 
0.027 
0.028 
0.022 
0.072 
0.071 
0.065 
0.099 
0.097 
0.094 
0.047 
0.050 
0.046 
0.026 
0.030 
0.028 
0.020 
0.018 
0.020 
0.058 
0.059 
0.057 
0.117 
0.119 
0.117 
0.022 
0.021 
0.020 
0.028 
0.030 
0.026 
0.045 
0.047 
0.044 
n=500 observed 
asymptotic 
bootstrap 
0.009 
0.009 
0.009 
0.012 
0.012 
0.011 
0.032 
0.031 
0.029 
0.045 
0.044 
0.042 
0.021 
0.021 
0.019 
0.012 
0.013 
0.012 
0.009 
0.008 
0.008 
0.025 
0.025 
0.022 
0.057 
0.056 
0.055 
0.009 
0.009 
0.009 
0.013 
0.013 
0.012 
0.021 
0.021 
0.019 
n=2000 observed 
asymptotic 
bootstrap 
0.005 
0.005 
0.005 
0.006 
0.006 
0.005 
0.015 
0.015 
0.014 
0.024 
0.022 
0.021 
0.011 
0.011 
0.010 
0.006 
0.006 
0.006 
0.004 
0.004 
0.004 
0.012 
0.012 
0.011 
0.028 
0.028 
0.028 
0.004 
0.005 
0.005 
0.006 
0.007 
0.006 
0.011 
0.011 
0.010 
95% coverage probability 
n=100 asymptotic 
bootstrapN  
bootstrapP  
91.7 
90.4 
93.6 
94.2 
88.2 
90.0 
94.0 
91.2 
92.4 
92.8 
91.2 
92.4 
94.9 
91.2 
93.4 
91.9 
92.4 
94.0 
88.0 
95.0 
96.4 
94.9 
93.6 
91.8 
90.8 
90.4 
93.4 
90.7 
90.4 
92.2 
94.1 
89.8 
93.6 
92.2 
93.2 
95.6 
n=500 asymptotic 
bootstrapN  
bootstrapP  
94.1 
93.3 
93.9 
95.4 
92.9 
93.1 
95.1 
93.5 
94.1 
93.8 
93.6 
94.7 
94.9 
94.0 
95.4 
94.9 
94.2 
94.8 
92.5 
91.4 
93.0 
95.0 
93.2 
91.6 
94.4 
93.0 
94.8 
94.3 
93.6 
94.6 
94.8 
93.8 
94.2 
94.2 
92.6 
93.8 
n=2000 asymptotic 
bootstrapN  
bootstrapP  
94.9 
94.4 
94.6 
95.2 
94.6 
95.4 
94.4 
94.2 
95.6 
94.8 
95.2 
95.2 
95.2 
95.4 
94.9 
95.2 
95.4 
95.4 
94.3 
93.2 
93.8 
94.6 
93.8 
94.8 
94.5 
93.6 
93.6 
94.7 
94.6 
94.6 
95.3 
94.8 
95.2 
94.5 
94.2 
94.8 
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Table 5: Results of simulations to evaluate the application of inference based on asymptotic distribution theory and bootstrap 
resampling to finite sample studies. Data are generated as described for Table 3. Shown are results for TPR(p), FPR(p), PPV(p) and 
NPV(p). 
 
  p=0.1 p=0.35 p=0.6 p=0.1 p=0.35 p=0.6 p=0.1 p=0.35 p=0.6 p=0.1 p=0.35 p=0.6 
  TPR(p)= FPR(p)= PPV(p)= NPV(p)= 
  0.905 0.395 0.098 0.622 0.103 0.011 0.267 0.490 0.691 0.941 0.856 0.814 
% Bias 
n=100  0.22 -0.69 21.42 -0.52 -4.09 3.32 2.07 3.16 -18.73 -0.21 0.14 0.39 
n=500  0.05  -0.27 4.26 -0.22 -0.41 2.38 0.51 0.75 -0.11 -0.03 0.05 0.09 
n=2000  0.01 -0.19 1.18 -0.19 -0.26 0.79 0.09 0.11 0.66 0.00 0.01 0.02 
Standard deviation 
n=100 observed 
asymptotic 
bootstrap 
0.037 
0.039 
0.037 
0.117 
0.114 
0.110 
0.090 
0.091 
0.089 
0.120 
0.115 
0.112 
0.037 
0.041 
0.038 
0.019 
0.018 
0.016 
0.037 
0.037 
0.038 
0.101 
0.113 
0.112 
0.189 
0.205 
0.200 
0.032 
0.025 
0.028 
0.023 
0.022 
0.022 
0.020 
0.020 
0.018 
n=500 observed 
asymptotic 
bootstrap 
0.017 
0.016 
0.015 
0.053 
0.052 
0.050 
0.041 
0.042 
0.041 
0.054 
0.052 
0.050 
0.017 
0.017 
0.015 
0.007 
0.008 
0.007 
0.017 
0.016 
0.016 
0.042 
0.041 
0.045 
0.135 
0.141 
0.132 
0.010 
0.009 
0.011 
0.010 
0.010 
0.010 
0.009 
0.009 
0.008 
n=2000 observed 
asymptotic 
bootstrap 
0.008 
0.008 
0.007 
0.027 
0.026 
0.025 
0.021 
0.021 
0.020 
0.027 
0.026 
0.025 
0.008 
0.008 
0.008 
0.004 
0.004 
0.004 
0.008 
0.008 
0.008 
0.020 
0.020 
0.021 
0.065 
0.065 
0.066 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
0.005 
95% coverage probability 
n=100 asymptotic 
bootstrapN  
bootstrapP  
92.9 
94.4 
97.4 
92.5 
90.6 
92.2 
89.2 
90.4 
93.2 
92.6 
91.0 
92.4 
96.7 
92.2 
92.6 
89.0 
86.0 
89.4 
94.2 
93.0 
92.8 
97.5 
97.2 
98.2 
95.8 
93.2 
90.5 
90.3 
94.2 
95.8 
93.3 
92.8 
93.6 
94.7 
92.4 
94.4 
n=500 asymptotic 
bootstrapN  
bootstrapP  
93.4 
92.0 
94.4 
94.1 
93.8 
94.2 
93.1 
92.2 
93.0 
93.7 
92.4 
93.4 
96.0 
93.4 
93.6 
94.2 
92.4 
94.0 
94.2 
93.2 
93.4 
95.3 
96.0 
97.4 
94.6 
95.2 
96.2 
92.8 
95.6 
96.8 
94.1 
92.2 
92.2 
94.9 
93.6 
94.8 
n=2000 asymptotic 
bootstrapN  
bootstrapP  
95.6 
95.8 
95.0 
93.7 
94.2 
94.8 
94.4 
93.4 
93.2 
94.2 
93.8 
94.2 
95.5 
94.7 
95.7 
95.1 
94.2 
95.7 
94.4 
95.0 
94.4 
95.3 
94.8 
96.6 
95.1 
96.2 
95.6 
94.0 
95.0 
96.4 
94.1 
94.2 
94.6 
94.8 
94.6 
95.2 
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Table 6: Results of simulations to evaluate the application of inference based on asymptotic 
distribution theory to finite sample studies. Data are generated as described for Table 3. Shown 
are results for PEV, standardized total gain, TG  and AUC. 
 
  PEV=0.154 TG =0.383 AUC=0.760 
% Bias 
n=100  7.09 0.97 0.05 
n=500  1.24 0.56 0.06 
n=2000  0.62 -0.13 -0.01 
Standard deviation 
n=100 observed 
asymptotic 
Bootstrap 
0.064 
0.071 
0.064 
0.092 
0.095 
0.096 
0.047 
0.047 
0.047 
n=500 observed 
asymptotic 
bootstrap 
0.029 
0.031 
0.028 
0.041 
0.042 
0.042 
0.021 
0.021 
0.021 
n=2000 observed 
asymptotic 
bootstrap 
0.015 
0.016 
0.016 
0.021 
0.021 
0.021 
0.011 
0.011 
0.011 
95% coverage probability 
n=100 asymptotic 
bootstrapN 
bootstrapP 
95.7 
93.2 
92.8 
94.8 
95.2 
96.8 
94.3 
93.0 
94.2 
n=500 asymptotic 
bootstrapN 
bootstrapP 
95.8 
95.4 
94.4 
95.0 
94.4 
94.2 
94.3 
95.0 
94.6 
n=2000 asymptotic 
bootstrapN 
bootstrapP 
96.5 
96.4 
95.4 
95.2 
94.6 
95.0 
94.8 
95.0 
95.0 
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Table 7: Point estimates and 95% confidence intervals for the summary indices using FEV1 and 
weight as markers of risk for subsequent pulmonary exacerbation in patients with cystic fibrosis. 
Results based on the entire cohort. 
 
  Standard 
deviation 
95% confidence interval  
 Estimate Asymptotic Asymptotic Percentile Bootstrap p-value 
R(0.9)      
FEV1 0.76 0.007 (0.745, 0.773) (0.746, 0.773) 
weight 0.52 0.006 (0.503, 0.537) (0.503, 0.527) 
<0.001 
R(0.1)      
FEV1 0.14 0.005 (0.129, 0.148) (0.129, 0.148) 
weight 0.24 0.007 (0.221, 0.251) (0.223, 0.252) 
<0.001 
R
-1
(0.25)      
FEV1 0.32 0.010 (0.305, 0.344) (0.303, 0.342) 
weight 0.11 0.009 (0.095, 0.131) (0.095, 0.134) 
<0.001 
R
-1
(0.75)      
FEV1 0.89 0.007 (0.875, 0.905) (0.874, 0.906) 
weight 1 0 (1, 1) (1, 1) 
<0.001 
R((TPR=0.85))      
FEV1 0.27 0.007 (0.253, 0.280) (0.254, 0.279) 
weight 0.32 0.007 (0.304, 0.330) (0.305, 0.332) 
<0.001 
R((TPR=0.55))      
FEV1 0.53 0.008 (0.511, 0.540) (0.512, 0.538) 
weight 0.47 0.005 (0.456, 0.477) (0.457, 0.477) 
<0.001 
R((FPR=0.15))      
FEV1 0.54 0.008 (0.525, 0.556) (0.524, 0.554) 
weight 0.51 0.006 (0.503, 0.527) (0.503, 0.527) 
<0.001 
R((FPR=0.45))      
FEV1 0.29 0.006 (0.282, 0.304) (0.283, 0.303) 
weight 0.43 0.005 (0.424, 0.443) (0.424, 0.443) 
<0.001 
TPR(0.25)      
FEV1 0.87 0.007 (0.853, 0.880) (0.852, 0.879) 
weight 0.93 0.007 (0.920, 0.947) (0.921, 0.946) 
<0.001 
TPR(0.75)      
FEV1 0.21 0.014 (0.185, 0.239) (0.186, 0.240) 
weight 0 0 (0, 0) (0, 0) 
<0.001 
FPR(0.25)      
FEV1 0.54 0.013 (0.517, 0.569) (0.519, 0.570) 
Weight 0.85 0.011 (0.832, 0.877) (0.831, 0.875) 
<0.001 
FPR(0.75)      
FEV1 0.039 0.004 (0.032, 0.046) (0.033, 0.045) 
weight 0 0 (0, 0) (0, 0) 
<0.001 
PPV(0.25)      
FEV1 0.53 0.005 (0.515, 0.535) (0.513, 0.536) 
weight 0.43 0.002 (0.427, 0.435) (0.428, 0.437) 
<0.001 
PPV(0.75)      
FEV1 0.79 0.011 (0.768, 0.811) (0.768, 0.814) 
weight 0 0 (0, 0) (0, 0) 
<0.001 
NPV(0.25)      
FEV1 0.83 0.005 (0.820, 0.842) (0.819, 0.840) 
Weight 0.76 0.011 (0.747, 0.780) (0.746, 0.778) 
<0.001 
NPV(0.75)      
FEV1 0.64 0.003 (0.630, 0.644) (0.630, 0.645) 
weight 0.59 0 (0.590, 0.590) (0.590, 0.590) 
<0.001 
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PEV      
FEV1 0.22 0.005 (0.202, 0.229) (0.203, 0.230) 
weight 0.05 0.003 (0.041, 0.056) (0.041, 0.056) 
<0.001 
TG      
FEV1 0.20 0.006 (0.189, 0.207) (0.186, 0.208) 
weight 0.09 0.005 (0.080, 0.099) (0.082, 0.101) 
<0.001 
TG       
FEV1 0.42 0.008 (0.407, 0.440) (0.407, 0.439) 
weight 0.20 0.009 (0.183, 0.218) (0.182, 0.218) 
<0.001 
AUC      
FEV1 0.77 0.004 (0.762, 0.779) (0.762, 0.780) 
weight 0.64 0.005 (0.630, 0.649) (0.630, 0.649) 
<0.001 
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Table 8: Point estimates and 95% confidence intervals for the summary indices using FEV1 and 
weight as markers of risk for subsequent pulmonary exacerbation in patients with cystic fibrosis. 
Results are based on prevalence estimated from the entire cohort and marker data from a 
randomly selected case-control subset with 1,280 cases and 1,280 controls. 
 
  Standard 
deviation 
95% confidence interval  
 Estimate Asymptotic Asymptotic Percentile 
Bootstrap 
p-value 
R(0.9)      
FEV1 0.76 0.014 (0.731, 0.785) (0.735, 0.788) 
weight 0.52 0.011 (0.494, 0.535) (0.496, 0.534) 
<0.001 
R(0.1)      
FEV1 0.14 0.009 (0.119, 0.155) (0.117, 0.152) 
weight 0.23 0.015 (0.204, 0.263) (0.197, 0.253) 
<0.001 
R
-1
(0.25)      
FEV1 0.35 0.014 (0.318, 0.375) (0.314, 0.367) 
weight 0.12 0.020 (0.086, 0.157) (0.089, 0.151) 
<0.001 
R
-1
(0.75)      
FEV1 0.88 0.013 (0.850, 0.903) (0.850, 0.903) 
weight 1 0 (1, 1) (1, 1) 
<0.001 
R((TPR=0.85))      
FEV1 0.26 0.008 (0.247, 0.277) (0.250, 0.278) 
weight 0.31 0.008 (0.299, 0.330) (0.300, 0.331) 
<0.001 
R((TPR=0.55))      
FEV1 0.55 0.014 (0.518, 0.573) (0.522, 0.573) 
weight 0.47 0.009 (0.458, 0.492) (0.455, 0.490) 
<0.001 
R((FPR=0.15))      
FEV1 0.53 0.010 (0.513, 0.551) (0.517, 0.550) 
weight 0.52 0.011 (0.498, 0.541) (0.500, 0.543) 
0.332 
R((FPR=0.45))      
FEV1 0.29 0.010 (0.267, 0.308) (0.266, 0.306) 
weight 0.43 0.005 (0.420, 0.441) (0.421, 0.442) 
<0.001 
TPR(0.25)      
FEV1 0.86 0.006 (0.848, 0.875) (0.850, 0.874) 
weight 0.93 0.011 (0.911, 0.954) (0.915, 0.950) 
<0.001 
TPR(0.75)      
FEV1 0.25 0.027 (0.195, 0.306) (0.198, 0.310) 
weight 0 0 (0, 0) (0. 0) 
<0.001 
FPR(0.25)      
FEV1 0.51 0.021 (0.465, 0.552) (0.476, 0.568) 
Weight 0.84 0.027 (0.794, 0.888) (0.792, 0.885) 
<0.001 
FPR(0.75)      
FEV1 0.04 0.005 (0.025, 0.045) (0.027, 0.045) 
weight 0 0 (0, 0) (0, 0) 
<0.001 
PPV(0.25)      
FEV1 0.54 0.011 (0.519, 0.561) (0.517, 0.558) 
weight 0.43 0.007 (0.423, 0.447) (0.422, 0.445) 
<0.001 
PPV(0.75)      
FEV1 0.80 0.018 (0.796, 0.868) (0.792, 0.870) 
weight 0 0 (0, 0) (0, 0) 
<0.001 
NPV(0.25)      
FEV1 0.84 0.008 (0.819, 0.854) (0.819, 0.851) 
Weight 0.77 0.016 (0.739, 0.804) (0.738, 0.806) 
<0.001 
NPV(0.75)      
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FEV1 0.65 0.008 (0.633, 0.666) (0.633, 0.669) 
weight 0.59 0 (0.590, 0.590) (0.590, 0.590) 
<0.001 
PEV      
FEV1 0.21 0.017 (0.181, 0.248) (0.184, 0.245) 
weight 0.04 0.008 (0.022, 0.054) (0.025, 0.053) 
<0.001 
TG      
FEV1 0.20 0.009 (0.182, 0.216) (0.182, 0.216) 
weight 0.09 0.009 (0.069, 0.104) (0.070, 0.104) 
<0.001 
TG       
FEV1 0.41 0.019 (0.368, 0.442) (0.370, 0.444) 
weight 0.21 0.020 (0.171. 0.251) (0.171, 0.252) 
<0.001 
AUC      
FEV1 0.768 0.009 (0.749, 0.786) (0.750, 0.787) 
weight 0.649 0.011 (0.625, 0.669) (0.628, 0.670) 
<0.001 
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Table 9: Point estimates and 95% confidence intervals for the summary indices using FEV1 and 
weight as markers of risk for subsequent pulmonary exacerbation in patients with cystic fibrosis. 
Results are based on prevalence estimated from the entire cohort and marker data from a 
randomly selected case-control subset with equal numbers of cases and controls. The total 
number of cases and controls is denoted by n. Confidence intervals and p-values were based on 
bootstrap resampling. 
 
Est. (95% CI)  
-FEV1 -weight 
p-value 
R(0.1) n=500 0.15 (0.100, 0.203) 0.28 (0.212, 0.371) <0.001 
 n=200 0.11 (0.049, 0.179) 0.22 (0.107, 0.335) 0.04 
 n=100 0.17 (0.077, 0.283) 0.16 (0.041, 0.299) 0.89 
     
R(0.9) n=500 0.80 (0.736, 0.862) 0.53 (0.470, 0.590) <0.001 
 n=200 0.69 (0.574, 0.795) 0.49 (0.401, 0.578) <0.001 
 n=100 0.66 (0.502, 0.835) 0.48 (0.337, 0.619) 0.004 
     
R
-1
(0.25) n=500 0.29 (0.173, 0.373) 0.12 (0.022, 0.216) <0.001 
 n=200 0.32 (0.125, 0.453) 0.14 (0, 0.286) 0.02 
 n=100 0.37 (0.126, 0.516) 0.10 (0, 0.331) 0.09 
     
R
-1
(0.75) n=500 0.87 (0.811, 0.934) 1 (1, 1) <0.001 
 n=200 0.85 (0.770, 0.960) 1 (1, 1) 0.005 
 n=100 0.86 (0.738, 0.966) 1 (0, 1) 0.61 
     
R(v(TPR=0.85)) n=500 0.25 (0.203, 0.304) 0.32 (0.283, 0.368) 0.002 
 n=200 0.27 (0.209, 0.346) 0.36 (0.273, 0.443) 0.008 
 n=100 0.25 (0.167, 0.366) 0.32 (0.227, 0.433) 0.10 
     
R(v(TPR=0.55)) n=500 0.53 (0.468, 0.614) 0.48 (0.426, 0.537) 0.04 
 n=200 0.56 (0.456, 0.702) 0.46 (0.375, 0.552) 0.05 
 n=100 0.61 (0.454, 0.828) 0.51 (0.387, 0.634) 0.16 
     
R(v(FPR=0.15)) n=500 0.58 (0.508, 0.626) 0.50 (0.439, 0.562) 0.006 
 n=200 0.55 (0.460, 0.632) 0.50 (0.414, 0.591) 0.25 
 n=100 0.48 (0.330, 0.607) 0.55 (0.404, 0.654) 0.42 
     
R(v(FPR=0.45)) n=500 0.28 (0.230, 0.344) 0.42 (0.379, 0.472) <0.001 
 n=200 0.29 (0.204, 0.378) 0.43 (0.357, 0.500) <0.001 
 n=100 0.33 (0.211, 0.444) 0.44 (0.327, 0.539) 0.03 
     
TPR(0.25) n=500 0.89 (0.837, 0.922) 0.93 (0.865, 0.974) 0.09 
 n=200 0.90 (0.845, 0.972) 1 (0, 1) 0.58 
 n=100 0.88 (0.731, 1.000) 0.96 (0, 1) 0.81 
     
TPR(0.75) n=500 0.20 (0.092, 0.320) 0 (0, 0) <0.001 
 n=200 0.26 (0.027, 0.460) 0 (0, 0) 0.08 
 n=100 0.22 (0, 0.451) 0 (0, 1) 0.44 
     
FPR(0.25) n=500 0.58 (0.474, 0.807) 0.82 (0.695, 0.956) 0.003 
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 n=200 0.57 (0.386, 0.816) 0.83 (0.553, 0.990) 0.03 
 n=100 0.72 (0.384, 0.980) 1 (0, 1) 0.53 
     
FPR(0.75) n=500 0.05 (0.023, 0.072) 0 (0, 0) <0.001 
 n=200 0.05 (0.004, 0.096) 0 (0, 0) 0.32 
 n=100 0.06 (0, 0.128) 0 (0, 1) 0.74 
     
PPV(0.25) n=500 0.50 (0.454, 0.543) 0.44 (0.408, 0.461) 0.01 
 n=200 0.49 (0.437, 0.575) 0.43 (0.409, 0.461) 0.05 
 n=100 0.46 (0.410, 0.613) 0.40 (0.396, 0.501) 0.29 
     
PPV(0.75) n=500 0.76 (0.626, 0.857) 0 (0, 0) <0.001 
 n=200 0.72 (0.563, 0.917) 0 (0, 0) <0.001 
 n=100 0.76 (0.555, 0.943) 0 (0, 0) <0.001 
     
NPV(0.25) n=500 0.85 (0.807, 0.885) 0.76 (0.696, 0.840) 0.02 
 n=200 0.85 (0.753, 0.909) 0.76 (0.448, 0.865) 0.42 
 n=100 0.80 (0.598, 0.907) 0.74 (0, 0.859) 0.77 
     
NPV(0.75) n=500 0.62 (0.593, 0.653) 0.59 (0.590, 0.590) 0.11 
 n=200 0.62 (0.590, 0.675) 0.59 (0.590, 0.590) 0.21 
 n=100 0.60 (0.587, 0.681) 0.59 (0.590, 0.590) 0.83 
     
PEV n=500 0.22 (0.158, 0.293) 0.04 (0.016, 0.082) <0.001 
 n=200 0.22 (0.119, 0.337) 0.07 (0.020, 0.148) 0.004 
 n=100 0.31 (0.163, 0.480) 0.08 (0.012, 0.215) 0.006 
     
TG n=500 0.19 (0.142, 0.222) 0.08 (0.030, 0.111) <0.001 
 n=200 0.23 (0.159, 0.281) 0.09 (0, 0.150) 0.001 
 n=100 0.29 (0.181, 0.353) 0.09 (-0.007, 0.198) 0.002 
     
TG  n=500 0.45 (0.39, 0.54) 0.21 (0.12, 0.29) <0.001 
 n=200 0.48 (0.35, 0.59) 0.25 (0.11, 0.37) 0.004 
 n=100 0.56 (0.38, 0.74) 0.24 (0.06, 0.42) 0.004 
     
AUC n=500 0.76 (0.72, 0.80) 0.63 (0.58, 0.68) <0.001 
 n=200 0.76 (0.69, 0.82) 0.64 (0.56, 0.71) 0.002 
 n=100 0.83 (0.75, 0.91) 0.70 (0.61, 0.79) 0.02 
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Figure 1: Predictiveness curves for FEV1 (solid curve) and weight (dashed curve) as predictors of the risk of having at least one 
pulmonary exacerbation in the following year in children with cystic fibrosis. The horizontal line indicates the overall proportion of 
the population with an event, r= 41%.  Using the low risk threshold, pL = 0.25, 11% of subjects are classified as low risk according to 
weight while 32% are classified as low risk according to FEV1.  
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Figure 2: Cumulative distributions of risk based on FEV1 and weight in predicting the risk of having at least one pulmonary 
exacerbation in the following year in children with cystic fibrosis. Distributions are shown separately for subjects who had events 
(cases, solid curve) and for subjects who did not (controls, dashed curve). According to FEV1, 13% of cases and 46% of controls are 
classified as low risk, while only 7% of cases and 15% of controls are assigned low risk status according to weight.  
(a) -FEV1
risk of disease
C
D
F
 o
f 
ri
s
k
0 low 0,4 0.6 high
0
0
.2
0
.4
0
.6
0
.8
1
.0
0.79
0.96
0.13
0.46
case
control
(b) -weight
risk of disease
C
D
F
 o
f 
ri
s
k
0.15 low 0.35 0.45
0
0
.2
0
.4
0
.6
0
.8
1
.0
0.07
0.15
case
control
 
 
 
 
 
 
 
Hosted by The Berkeley Electronic Press
 86 
Figure 3: ROC curves for FEV1 (solid curve) and weight (dashed curve) as predictors of risk of having at least one pulmonary 
exacerbation in the following year in children with cystic fibrosis. The solid and filled circles are the true and false positive rates 
corresponding to the low risk threshold pL = 0.25. The areas under the ROC curve are 0.771 for FEV1 and 0.639 for weight.  
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Figure 4: Relationship between the proportion of explained variation, PEV, and the prevalence r . A linear logistic risk model with 
controls standard normally distributed and cases normally distributed with mean 1 and variance 1 was used to generate the data. 
Maximum PEV occurs at r=0.5. 
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Figure 5: Association between )}()({ pFPRpTPR - and p. A linear logistic risk model with controls standard normally distributed and 
cases normally distributed with mean 1 and variance 1 was used to generate the data. Overall prevalence of event r=0.2. Maximum 
value, also known as the Kolmogorov-Smirnov distance, occurs at p= r . 
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